

10088060

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626KAS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 May 12 EXTEND option available in structure searching
NEWS 4 May 12 Polymer links for the POLYLINK command completed in REGISTRY
NEWS 5 May 27 New UPM (Update Code Maximum) field for more efficient patent
SDIs in Caplus
NEWS 6 May 27 Caplus super roles and document types searchable in REGISTRY
NEWS 7 Jun 22 STN Patent Forums to be held July 19-22, 2004
NEWS 8 Jun 28 Additional enzyme-catalyzed reactions added to CASREACT
NEWS 9 Jun 28 ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG,
and WATER from CSA now available on STN(R)

NEWS EXPRESS MARCH 31 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 26 APRIL 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:13:15 ON 12 JUL 2004

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:13:23 ON 12 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Kamal Saeed

10088060

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 11 JUL 2004 HIGHEST RN 708207-86-7
DICTIONARY FILE UPDATES: 11 JUL 2004 HIGHEST RN 708207-86-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>


Uploading 10088060.str

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 10:13:46 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - >1,000,000 TO ITERATE

< 14.4% PROCESSED 279397 ITERATIONS

330 ANSWERS

< 18.6% PROCESSED 360718 ITERATIONS

341 ANSWERS

Kamal Saeed

10088060

< 20.6% PROCESSED 400000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.46

341 ANSWERS

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: EXCEEDS 1000000
PROJECTED ANSWERS: EXCEEDS 1532

L2 341 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

155.84

156.05

FILE 'CAPLUS' ENTERED AT 10:14:45 ON 12 JUL 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 12 Jul 2004 VOL 141 ISS 3
FILE LAST UPDATED: 11 Jul 2004 (20040711/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2

L3 16 L2

=> d ibib abs hitstr tot

10088060

L3 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2004:220301 CAPLUS
 DOCUMENT NUMBER: 140:270550
 TITLE: A preparation of 1,3-diamino-2-hydroxypropane derivatives as beta-secretase enzyme inhibitors
 INVENTOR(S): Fobian, Yvette M.; Freskos, John N.; Jagodzinska, Barbara
 PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn
 SOURCE: PCT Int. Appl., 535 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022523	A2	20040318	WO 2003-US28116	20030908
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GR, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPL. INFO.: US 2002-408783P P 20020906
 OTHER SOURCE(S): MARPAT 140:270550
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to diamino(hydroxy)propane deriva. of formula I [wherein: R1 = -(CH2)1-2-S(O)0-2-(C1-6 alkyl) or (un)substituted (cyclo)alkyl, alk(en/yn)yl, (hetero)aryl, etc.; R2 = H, C1-6 alkyl optionally substituted with 1-3 substituents, (CH2)0-4-(hetero)aryl, C2-6 alk(en/yn)yl, etc.; R3 = H, C1-6 alkyl optionally substituted with 1-3 substituents, (CH2)0-4-(hetero)aryl, etc.; R4 = C1-10 alkyl optionally substituted with 1-3 substituents, -(CH2)0-3-cycloalkyl, -(CH2)0-4-(hetero)aryl, etc.; one of R5 and R6 is H and the other is -C(O)(CR9R10)1-6-X-R11, etc.; R7 and R8 are independently selected from H, alkyl, hydroxyalkyl, alk(en/yn)yl, etc.; R9 and R10 are independently selected from H or C1-10 alkyl; R11 = (hetero)aryl, optionally substituted C1-10 alkyl, or C3-8 cycloalkyl, etc.; X = O, S, SO2, etc.]. Comps. I include inhibitors of beta-secretase enzyme useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta-peptide in a mammal. Biol. examples include beta-secretase inhibition, assays using synthetic oligopeptide-substrates, inhibition of

L3 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 674315-02-7 CAPLUS
 CN 1,3-Benzenedicarboxamide, N-[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-N-[(1S)-2-(ethylamino)-1-methyl-2-oxoethyl]-5-methyl-N',N'-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 674315-26-5 CAPLUS
 CN .beta.-Alanine, N-[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-N-[(1S)-2-(dipropylamino)carbonyl]-5-methylbenzoyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 674315-49-2 CAPLUS
 CN 1,3-Benzenedicarboxamide, N-[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-5-methyl-N-[(1S)-1-[(methylamino)carbonyl]-3-(methylthio)propyl]-N',N'-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 A beta prodn. in human patients, etc. For instance, compd. II (prepn. 8) was prepd. via amidation of benzoic acid deriv. III by diamino(hydroxy)propane deriv. IV and subsequent Boc-cleavage (no yield data). Using 19F-NMR an intramol. acyl-migration was obsd. when compd.

II was dissolved in DMSO-d6 and pH 4 buffer soln. was added.


IT 674313-29-2P 674315-02-7P 674315-26-5P
 674315-49-2P 674316-49-3P 674317-08-9P
 674319-16-5P 674320-60-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of diamino(hydroxy)propane deriva. useful as beta-secretase inhibitors)

RN 674313-29-2 CAPLUS


CN 1,3-Benzenedicarboxamide, N-[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-5-methyl-N-[(1S)-1-[(2-methylpropyl)amino]carbonyl]-3-(methylthio)propyl]-N',N'-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A

PAGE 2-A




L3 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 674316-49-5 CAPLUS
 CN 1,3-Benzenedicarboxamide, N-[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-5-methyl-N-[(1S)-1-methyl-2-oxo-2-[(phenylmethyl)amino]ethyl]-N',N'-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Kamal Saeed

10088060


L3 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 674317-08-9 CAPLUS
 CN 1,3-Benzenedicarboxamide, N-[(1S)-1-(aminocarbonyl)-3-methylbutyl]-N-[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-5-methyl-N',N'-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 674319-16-5 CAPLUS
 CN 1,3-Benzenedicarboxamide, N-[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-N-(2-amino-1-methyl-2-oxoethyl)-5-methyl-N',N'-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 674320-60-6 CAPLUS
 CN 1,3-Benzenedicarboxamide, N-[(2R,3S)-3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-N-[(1S)-1-(hydroxymethyl)-2-(methylamino)-2-oxoethyl]-5-methyl-N',N'-dipropyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2004:57292 CAPLUS
 DOCUMENT NUMBER: 140:117455
 TITLE: Stents including soluble guanylate cyclase (sGC) activators
 INVENTOR(S): Alonao-Alija, Cristina; Stelte-Ludwig, Beatrix; Grunkemeyer, Jeffrey-Lynn; Staach, Johannes-Peter
 PATENT ASSIGNEE(S): Bayer A.-G., Germany
 SOURCE: Ger. Offen., 7 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10231336	A1	20040122	DE 2002-10231336	20020711
WO 2004006975	A1	20040122	WO 2003-EP6897	20030630

W: AZ, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AL, BY, KG, KZ, MD, RU, RW, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


PRIORITY APPLN. INFO.: DE 2002-10231336 A 20020711
 OTHER SOURCE(S): MARPAT 140:117455

AB The invention concerns stents that include 4-[[[4-carboxybutyl]-[2-[[4-phenethylbenzyl]oxy]phenethyl]amino]methyl]-benzoic acid or its hydrochloride as guanylate cyclase (sGC) activators. Addnl. the stents can be coated with a membrane and it can include other drugs. The medicated stents are used to prevent restenosis and thrombosis after percutaneous transluminal coronary angioplasty (PTCA). Metal or non-biodegradable polymer stents can be filled or coated with the drug; drugs can be also mixed into the polymer matrix.


IT 646995-35-9
 RI: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (stents including sol. guanylate cyclase (sGC) activators)

RN 646995-35-9 CAPLUS
 CN Benzoic acid, 4-[[[4-carboxybutyl]-[2-[[4-(2-phenylethyl)phenyl]methoxy]phenyl]ethyl]amino]methyl]-, hydrochloride (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L3 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



● HCl

10088060

L3 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:892746 CAPLUS

DOCUMENT NUMBER: 139:395831

TITLE: Preparation of tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity

INVENTOR(S): Jiao, Richard; Goble, Stephen D.; Mills, Sander G.; Morriello, Gregori; Pasternak, Alexander; Yang, Lihui; Zhou, Changyou; Butora, Gabor; Kothandaraman, Shankaran; Guadeen, Deodiasingh; Moyes, Christopher

PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Merck Sharp & Dohme Limited

SOURCE: PCT Int. Appl., 267 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093231	A2	20031113	WO 2003-US13121	20030425
W:				
AZ, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPL. INFO.: US 2002-376407P P 20020429

OTHER SOURCE(S): MARPAT 139:395831

GI

L3 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




AB Title compds. I (X = O, S, SO, NH, CR11R12, etc.; R1 = OH, heterocycle, (un)substituted alkyl, alkyloxyalkyl, CN, etc.; R2 = H, OH, halo, heterocycle, (un)substituted alkyl, etc.; R3 = H, OH, halo, CN, NO2, alkythio, alkylamine, etc.; R4 = F3C, F3CO, H, alkyl, Cl, F, Br, and Ph; R5 = (un)substituted alkyl, alkoxy, alkythio, pyridyl, F, Cl, Br, heterocycle, etc.; R6 = H, alkyl, F3C, F, Cl, Br; R7 = H, (un)substituted alkyl; R8 = H, F, (un)substituted alkyl, OH, cycloalkyl, etc.; R9 = H, OH,

(un)substituted alkyl, carboxylate, alkoxy, or R8 and R9 may be joined together by a alkyl chain or alkyloxyalkyl chain to form a 3-6 membered ring; R10 = H, F, cycloalkyloxy, (un)substituted alkoxy, alkyl, or R8 and R10 may be joined together to form a (un)substituted carbocycle or heterocycle; R11 and R12 = independently H, OH, (un)substituted alkyl, benzyl, alkoxy, etc.; n = 0, 1, and 2) and their pharmaceutically acceptable salts are prepd. and disclosed as modulators of chemokine receptor activity. Thus, II was prepd. by condensation of the precursor aminocyclopentane deriv. (prepn. given) with tetrahydro-4H-pyran-4-one. In particular, these compds. are useful as modulators of the chemokine receptor CCR-2. I had activity in binding to the CCR-2 receptor generally with an IC50 of less than about 1 .mu.M.

IT 625127-19-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Intermediate; prepn. of tetrahydropyranyl cyclopentyl tetrahydroisoquinolines as modulators of chemokine receptor activity)

RN 625127-19-7 CAPLUS
CN Benzoic acid, 2-[(2-ethoxy-2-oxoethyl)(phenylmethyl)amino]methyl-4-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L3 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:723071 CAPLUS

DOCUMENT NUMBER: 139:392642

TITLE: Design of N-substituted Peptomer Ligands for EVH1 Domains

AUTHOR(S): Zimmermann, Juergen; Kuehne, Ronald; Volkmer-Engert, Rudolf; Jarchau, Thomas; Walter, Ulrich; Oschkinat, Hartmut; Bell, Linda J.

CORPORATE SOURCE: Forschungsinstitut fuer Molekulare Pharmakologie, Humboldt Universitaet zu Berlin, Berlin, 13125, Germany

SOURCE: Journal of Biological Chemistry (2003), 278(38), 36810-36818

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular Biology

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Ena/VASP proteins are implicated in cytoskeletal reorganization during actin-dependent motility processes. Recruitment to subcellular sites of actin polym. is mediated by the highly conserved N-terminal EVH1 domain, which interacts with target proteins contg. proline-rich motifs. The

VASP EVH1 domain specifically binds peptides with the consensus motif FPPPP present in all its binding partners, including the Listerial ActA protein.

Previous studies have shown that the Phe and first and final Pro residues are highly conserved and cannot be substituted with any other natural amino acid without significant loss of binding affinity. We have incorporated peptoid building blocks (sarcosine derived, non-natural amino

acids) into the peptide SPEFPPPPTEDEL from the Listerial ActA protein and were able to substitute the most highly conserved residues of this motif while maintaining binding to the VASP EVH1 domain with affinities in the range of 45-180 .mu.M. We then used NMR chem. shift perturbations to locate specific domain residues involved in particular interactions. These studies may open up the way for designing selective modulators of VASP function for biol. studies and for the development of novel therapeutics for diseases involving pathol. altered cell adhesion or cell motility.

IT 625458-19-7 625458-20-0 625458-22-2
625458-23-3 625458-24-4 625458-26-6
625458-27-7
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(design of N-substituted peptomer ligands for EVH1 domains)


RN 625458-19-7 CAPLUS
CN L-Leucine,
L-seryl-L-phenylalanyl-L-.alpha.-glutamyl-L-phenylalanyl-N-[(4-methoxyphenyl)methyl]glycyl-L-prolyl-L-prolyl-N-(2-hydroxy-2-phenylethyl)glycyl-L-threonyl-L-.alpha.-glutamyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10088060

L3 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



L3 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


PAGE 1-B



RN 625458-22-2 CAPLUS
CN L-Leucine, L-seryl-L-phenylalanyl-L-.alpha.-glutamyl-L-phenylalanyl-N-(3-phenylpropyl)glycyl-L-prolyl-L-prolyl-N-[(2,4-dichlorophenyl)methyl]glycyl-L-threonyl-L-.alpha.-glutamyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



L3 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


PAGE 2-B



RN 625458-20-0 CAPLUS
CN L-Leucine, L-seryl-L-phenylalanyl-L-.alpha.-glutamyl-L-phenylalanyl-N-(3-phenylpropyl)glycyl-L-prolyl-L-prolyl-N-(phenylmethyl)glycyl-L-threonyl-L-.alpha.-glutamyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L3 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-B



PAGE 2-A




RN 625458-23-3 CAPLUS
CN L-Leucine, L-seryl-L-phenylalanyl-L-.alpha.-glutamyl-L-phenylalanyl-N-(3-phenylpropyl)glycyl-L-prolyl-L-prolyl-N-[(4-methoxyphenyl)methyl]glycyl-L-threonyl-L-.alpha.-glutamyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10088060

L3 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




RN 625458-24-4 CAPLUS
CN L-Leucine, L-seryl-L-phenylalanyl-L-.alpha.-glutamyl-L-phenylalanyl-N-[(2,4-dichlorophenyl)methyl]glycyl-L-prolyl-L-prolyl-N-(2-hydroxy-2-phenylethyl)glycyl-L-threonyl-L-.alpha.-glutamyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B



L3 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


PAGE 2-B



RN 625458-26-6 CAPLUS
CN L-Leucine, L-seryl-L-phenylalanyl-L-.alpha.-glutamyl-L-phenylalanyl-N-[(2,4-dichlorophenyl)methyl]glycyl-L-prolyl-L-prolyl-N-(phenylmethyl)glycyl-L-threonyl-L-.alpha.-glutamyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




L3 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-B



PAGE 2-B




RN 625458-27-7 CAPLUS
CN L-Leucine, L-seryl-L-phenylalanyl-L-.alpha.-glutamyl-L-phenylalanyl-N-(3-phenylpropyl)glycyl-L-prolyl-L-prolyl-N-(3-phenylpropyl)glycyl-L-threonyl-L-.alpha.-glutamyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10088060

L3 ANSWER 4 OF 16 CAPIUS COPYRIGHT 2004 ACS on STN (Continued)


PAGE 1-A



PAGE 1-B

CO₂H

PAGE 2-A



REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L3 ANSWER 5 OF 16 CAPIUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:678833 CAPIUS
DOCUMENT NUMBER: 139:219317
TITLE: Compositions for transporting cyclosporin derivatives

INVENTOR(S): Mouchet, Patrick; Rees, Anthony R.; Elmer, Eskil; Keep, Marcus Floyd

PATENT ASSIGNEE(S): Syntem, Fr.; Maas Biolab, L.L.C.

SOURCE: PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003070755	A2	20030828	WO 2003-FR591	20030224
WO 2003070755	A3	20040304		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

FR 2836474 A1 20030829 FR 2002-2299 20020222

PRIORITY APPLN. INFO.: FR 2002-2299 A 20020222

OTHER SOURCE(S): MARPAT 139:219317
AS The invention concerns a compd. comprising at least a cyclosporin mol. and

at least a peptide vector capable of transporting said mol. through the blood brain barrier. The invention also concerns the use of the compd. for prep. pharmaceutical compns. in particular for treating or preventing

disease of the central nervous system. Cyclosporin peptide conjugates were prepd. and their transport through the blood brain barrier was demonstrated.

IT 590362-73-SP 590362-74-SP 590362-75-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(compns. transporting cyclosporin deriva. through blood brain barrier)

RN 590362-73-5 CAPIUS

CN Cyclosporin A, ester with


(4R)-1-[(1,1-dimethylethoxy)carbonyl]-4-hydroxy-L-prolyl-N-(phenylmethyl)glycine (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.

L3 ANSWER 4 OF 16 CAPIUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B




Kamal Saeed

10088060


L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-C



RN 590362-74-6 CAPLUS
 CN Cyclosporin A, (6.fwdarv.2')-ester with
 (4R)-4-(3-carboxy-1-oxopropoxy)-1-
 [(1,1-dimethylethoxy)carbonyl]-L-prolyl-N-(phenylmethyl)glycine (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry as shown.




PAGE 1-A

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-B



PAGE 1-C




RN 590362-75-7 CAPLUS
 CN Cyclosporin A, (6.fwdarv.2')-ester with
 (4R)-4-(3-carboxy-1-oxopropoxy)-1-
 [(1,1-dimethylethoxy)carbonyl]-L-prolyl-N-(phenylmethyl)glycine
 (1'.fwdarv.1'')-amide with
 L-arginyl-L-arginyl-L-leucyl-L-seryl-L-tyrosyl-
 L-seryl-L-arginyl-L-arginyl-L-arginyl-L-phenylalanine (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.
 Double bond geometry as shown.

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




PAGE 1-B




L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-C





PAGE 1-D



10088060

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-E




PAGE 2-D

L3 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:656749 CAPLUS
 DOCUMENT NUMBER: 139:197386
 TITLE: Preparation of isoquinolinone derivatives as JNK inhibitors
 INVENTOR(S): Itoh, Fumio; Kimura, Hiroyuki; Igata, Hideki; Kawamoto, Tomohiro; Sasaki, Mitsuru; Kitamura, Shuji
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 369 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003068750	A1	20030821	WO 2003-JP1429	20030212
M: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GW, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2004143134	A2	20040520	JP 2003-35096	20030213
PRIORITY APPLN. INFO.: JP 2002-35073 A 20020213 JP 2002-251997 A 20020829				


OTHER SOURCE(S): MARPAT 139:197386
 AB Claimed are JNK (c-Jun N-terminal kinase) inhibitors contg. isoquinolinones or salts thereof. The second claim specifies that said isoquinolinones are 1-isoquinolinones. Comps. of this invention in vitro showed IC50 values of 0.0067 .mu.M to 0.095 .mu.M against JNK1. Formulations are given.
 IT 583838-25-9P 583838-27-1P 583838-30-6P
 583838-35-1P 583838-41-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of isoquinolinone derivs. as JNK inhibitors)
 RN 583838-25-9 CAPLUS
 CN Benzamide, 2-benzoyl-4-bromo-N-[(4-methoxyphenyl)methyl]-N-(2-oxobutyl)-(9CI) (CA INDEX NAME)



Kamal Saeed


L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 2-E




L3 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 583838-27-1 CAPLUS
 CN Benzamide, 2-benzoyl-4-bromo-N-[(4-(methylsulfonyl)phenyl)methyl]-N-(2-oxopentyl)-(9CI) (CA INDEX NAME)




RN 583838-30-6 CAPLUS
 CN Benzamide, 2-benzoyl-4-bromo-N-[(4-(methylsulfonyl)phenyl)methyl]-N-(2-oxohexyl)-(9CI) (CA INDEX NAME)



RN 583838-35-1 CAPLUS
 CN Benzamide, 2-benzoyl-4-bromo-N-[(4-(methylsulfonyl)phenyl)methyl]-N-(2-oxo-3-phenylpropyl)-(9CI) (CA INDEX NAME)


10088060

L3 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 583838-41-9 CAPLUS

CN Benzoic acid, 4-[[[(2-benzoyl-4-chlorobenzoyl) (2-oxopropyl)amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.

FORMAT

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN

ACCESSION NUMBER: 2003:610410 CAPLUS

DOCUMENT NUMBER: 139:179889

TITLE: Methylene amides, particularly [(arylmethyl)amino] (oxo)acetic acids, useful as modulators, and especially inhibitors, of protein tyrosine phosphatases (PTPs), and their preparation, uses, e.g., as antidiabetics, and pharmaceutical compositions.

INVENTOR(S): Swinnen, Dominique; Bombrun, Agnes; Gonzalez, Jerome; Gerber, Patrick; Pittet, Pierre-Andre

PATENT ASSIGNEE(S): Applied Research Systems ARS Holding N.V., Neth. Antilles

SOURCE: PCT Int. Appl., 346 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003064376	A1	20030807	WO 2003-EP808	20030127
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TH, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				



PRIORITY APPL. INFO.: EP 2002-100078 A 20020129

EP 2002-100410 A 20020425

OTHER SOURCE(S): HARPAT 139:179889

GI

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



AB Title compds. I (wherein R1 = alkyl, alkenyl, alkynyl, aryl, heteroaryl, (3-8-membered)-cycloalkyl, heterocycloalkyl, (alkyl)aryl, (alkyl)heteroaryl, (alkenyl)aryl, heteroaryl, (alkynyl)aryl, heteroaryl; R2, R3 = independently H or alkyl; Cy = aryl, heteroaryl, cycloalkyl, heterocyclyl; with the proviso that four compds. are excluded: their geometrical isomers, optically active forms as enantiomers, diastereomers and racemates, and pharmaceutically acceptable salts and active derivs.) were prepd. as inhibitors of protein tyrosine phosphatases (PTPs), in particular PTP1B. Examples include over 400 invention compds., five pharmaceutical formulations, and two biol. assays. For example, II was prepd. in 4 steps by amidation of 4-formylbenzoic acid with dodecylamine in THF in the presence of 4-methylmorpholine and iso-Bu chloroformate for 3 h at room temp., reductive amination with 4-trifluoromethylbenzylamine in DCE in the presence of NaBH(OAc)3, TEA-acylation with chlorooxoacetic acid Et ester in THF, and base-catalyzed hydrolysis of the ester. II exhibited an IC50 value of 2.224 .mu.M for inhibition of PTP1B, 1.40 .mu.M for GLEPP-1, 2.40 .mu.M for SHP-1, and 2.70 .mu.M for SHP-2 in an in vitro assay. In an in vivo postprandial glycemia model in db/db mice, II, at 20-200 mg/kg orally, decreased blood glucose level by 17% at 20 mg/kg, by 42% at 100 mg/kg, and by 48% at 200 mg/kg, with decreases in serum insulin levels of -24, 66%, and 89%, resp. Thus, I and their formulations are useful for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS).

IT 578021-80-4P, [Benzyl[4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578021-81-5P, Oxo[4-[(pentadecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578021-82-6P, [Benzyl[4-[(tridecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578021-83-7P, [Benzyl[4-[(tridecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578021-84-8P, [Benzyl[4-[(dodecyl(methyl)amino)carbonyl]benzyl]amino] (oxo)acetic acid 578021-85-9P, [4-[(dodecyl(methyl)amino)carbonyl]benzyl]amino] (oxo)acetic acid 578021-87-1P, [4-[(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578021-88-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578021-89-3P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578021-90-4P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578021-91-5P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578021-92-6P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578021-93-7P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578021-94-8P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578021-95-9P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578021-96-0P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578021-97-1P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578021-98-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578021-99-3P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-00-4P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-01-5P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-02-6P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-03-7P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-04-8P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-05-9P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-06-0P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-07-1P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-08-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-09-3P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-10-4P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-11-5P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-12-6P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-13-7P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-14-8P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-15-9P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-16-0P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-17-1P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-18-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-19-3P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-20-4P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-21-5P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-22-6P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-23-7P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-24-8P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-25-9P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-26-0P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-27-1P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-28-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-29-3P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-30-4P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-31-5P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-32-6P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-33-7P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-34-8P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-35-9P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-36-0P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-37-1P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-38-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-39-3P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-40-4P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-41-5P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-42-6P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-43-7P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-44-8P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-45-9P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-46-0P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-47-1P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-48-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-49-3P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-50-4P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-51-5P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-52-6P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-53-7P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-54-8P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-55-9P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-56-0P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-57-1P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-58-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-59-3P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-60-4P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-61-5P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-62-6P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-63-7P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-64-8P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-65-9P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-66-0P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-67-1P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-68-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-69-3P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-70-4P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-71-5P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-72-6P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-73-7P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-74-8P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-75-9P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-76-0P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-77-1P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-78-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-79-3P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-80-4P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-81-5P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-82-6P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-83-7P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-84-8P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-85-9P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-86-0P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-87-1P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-88-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-89-3P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-90-4P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-91-5P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-92-6P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-93-7P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-94-8P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-95-9P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-96-0P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-97-1P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-98-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-99-3P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-00-4P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-01-5P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-02-6P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-03-7P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-04-8P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-05-9P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-06-0P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-07-1P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-08-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-09-3P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-10-4P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-11-5P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-12-6P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-13-7P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-14-8P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-15-9P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-16-0P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-17-1P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-18-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-19-3P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-20-4P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-21-5P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-22-6P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-23-7P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-24-8P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-25-9P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-26-0P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-27-1P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-28-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-29-3P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-30-4P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-31-5P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-32-6P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-33-7P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-34-8P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-35-9P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-36-0P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-37-1P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-38-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-39-3P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-40-4P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-41-5P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-42-6P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-43-7P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-44-8P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-45-9P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-46-0P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-47-1P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-48-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-49-3P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-50-4P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-51-5P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-52-6P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-53-7P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-54-8P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-55-9P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-56-0P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-57-1P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-58-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-59-3P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-60-4P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-61-5P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-62-6P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-63-7P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-64-8P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-65-9P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-66-0P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-67-1P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-68-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-69-3P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-70-4P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-71-5P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-72-6P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-73-7P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-74-8P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-75-9P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-76-0P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-77-1P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-78-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-79-3P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-80-4P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-81-5P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-82-6P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-83-7P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-84-8P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-85-9P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-86-0P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-87-1P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-88-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-89-3P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-90-4P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-91-5P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-92-6P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-93-7P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-94-8P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-95-9P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-96-0P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-97-1P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-98-2P, [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-99-3P,

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

hydroxybenzyl)amino] (oxo)acetic acid 578022-59-0P,
[[3-[(Dodecylamino)carbonyl]benzyl] (4-phenoxybenzyl)amino] (oxo)acetic acid

578022-61-4P, 3-[[[(Carboxycarbonyl) 3-[(dodecylamino)carbonyl]benzyl]amino]methyl]benzoic acid
578022-62-5P, 5-[[[(Carboxycarbonyl) 3-[(dodecylamino)carbonyl]benzyl]amino]methyl]-2-thiophenecarboxylic acid
578022-63-6P, [[4-[(Dodecylamino)carbonyl]benzyl] (4-nitrobenzyl)amino] (oxo)acetic acid 578022-65-0P,
[[4-[(Dodecylamino)carbonyl]benzyl] (2-fluorobenzyl)amino] (oxo)acetic acid 578022-66-9P, [[4-[(Dodecylamino)carbonyl]benzyl] (4-phenoxybenzyl)amino] (oxo)acetic acid 578022-67-0P,

4-[[[(Carboxycarbonyl) 4-[(dodecylamino)carbonyl]benzyl]amino]methyl]benzoic acid 578022-68-1P, 5-[[[(Carboxycarbonyl) 4-[(dodecylamino)carbonyl]benzyl]amino]methyl]-2-thiophenecarboxylic acid 578022-71-6P, [(3,5-Dichlorobenzyl) 4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-72-7P

[(3,5-Dichlorobenzyl) 4-[[[(3,3-diphenylpropyl)amino]carbonyl]benzyl]amino] (oxo)acetic acid 578022-73-8P, [[4-[[[(2,1,1'-Biphenyl)-4-ylethyl]amino]carbonyl]benzyl] (3,5-dichlorobenzyl)amino]glyoxylic acid 578022-78-3P, [[4-[(Dimethylamino)benzyl] 4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-80-7P, [(4-Cyanobenzyl) 4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-85-2P, [(3-[(Dodecylamino)carbonyl]benzyl] (3-hydroxybenzyl)amino] (oxo)acetic acid 578022-86-9P, [(4-Cyanobenzyl) 3-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-93-2P, [[4-[(Dodecylamino)carbonyl]benzyl] (4-hydroxybenzyl)amino] (oxo)acetic acid 578022-94-3P,

3-[[[(Carboxycarbonyl) 4-[(dodecylamino)carbonyl]benzyl]amino]methyl]benzoic acid 578023-11-7P, [[1-[(Cyclohexylamino)carbonyl]-4-piperidinyl]methyl] 4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-12-8P, [[1-[(4-[Oxobutyl]amino)carbonyl]piperidinyl]methyl] 4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578023-13-9P, [[4-[(Dodecylamino)carbonyl]benzyl] (1-hexanoyl)-4-piperidinyl]methyl]amino] (oxo)acetic acid 578023-14-0P, [[4-[(Dodecylamino)carbonyl]benzyl] [[1-(3-iodobenzyl)-4-piperidinyl]methyl]amino]glyoxylic acid 578023-15-1P,

[[4-[(Dodecylamino)carbonyl]benzyl] [[1-[(2E)-3-[3-(trifluoromethyl)phenyl]-2-propenoyl]-4-piperidinyl]methyl]amino]glyoxylic acid 578023-16-2P, [[1-[(4-quinolalyl)carbonyl]-4-piperidinyl]methyl]amino]glyoxylic acid 578023-18-4P, [[1-[(3-iodobenzyl)-4-piperidinyl]methyl] 4-[(4-phenoxybenzyl)amino]carbonyl]benzyl]amino] (oxo)acetic acid 578023-19-5P, Oxo[[4-[[[(4-phenoxybenzyl)amino]carbonyl]benzyl] [[1-[(2E)-3-[3-(trifluoromethyl)phenyl]-2-propenoyl]-4-piperidinyl]methyl]amino]acetic acid 578023-21-9P, [[4-[[[(2,1,1'-Biphenyl)-4-ylethyl]amino]carbonyl]-2-bromobenzyl] (4-iodobenzyl)amino]glyoxylic acid 578023-22-0P, [[2-Bromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl] (4-iodobenzyl)amino] (oxo)acetic acid 578023-23-1P,

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

578023-56-0P, [[2-Bromo-4-[(dodecylamino)carbonyl]benzyl] [[2'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl]amino]glyoxylic acid 578023-57-1P, [[4-[[[(2,1,1'-Biphenyl)-4-ylethyl]amino]carbonyl]-2,6-dibromobenzyl] [[2'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl]amino]glyoxylic acid 578023-58-2P, [[2,6-Dibromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl] [[2'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl]amino]glyoxylic acid 578023-59-3P, [[2,6-Dibromo-4-[(dodecylamino)carbonyl]benzyl] [[2'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl]amino]glyoxylic acid 578023-61-7P, [[4-[[[(2,1,1'-Biphenyl)-4-ylethyl]amino]carbonyl]-2-bromobenzyl] (1,1'-biphenyl-2-ylmethyl)amino]glyoxylic acid 578023-62-8P, [[1,1'-Biphenyl-2-ylmethyl] (2-bromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl]amino]glyoxylic acid 578023-63-9P, [(1,1'-Biphenyl-2-ylmethyl) (2-bromo-4-[(dodecylamino)carbonyl]benzyl]amino]glyoxylic acid 578023-64-0P, [(1,1'-Biphenyl-2-ylmethyl) (2,6-dibromo-4-[[[(2-(4-phenoxyphenyl)ethyl]amino]carbonyl]benzyl]amino]glyoxylic acid 578023-65-1P, [[4-[[[(2,1,1'-Biphenyl)-4-ylethyl]amino]carbonyl]-2,6-dibromobenzyl] (1,1'-biphenyl-2-ylmethyl)amino]glyoxylic acid 578023-66-2P, [(1,1'-Biphenyl-2-ylmethyl) (2,6-dibromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl]amino]glyoxylic acid 578023-67-3P, [(1,1'-Biphenyl-2-ylmethyl) (2,6-dibromo-4-[(dodecylamino)carbonyl]benzyl]amino]glyoxylic acid 578023-68-4P, [[2-Bromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl] 4-[(trifluoromethoxy)benzyl]amino] (oxo)acetic acid 578023-69-5P, [[2-Bromo-4-[(dodecylamino)carbonyl]benzyl] 4-[(trifluoromethoxy)benzyl]amino] (oxo)acetic acid 578023-70-6P, [[2,6-Dibromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl] 4-[(trifluoromethoxy)benzyl]amino] (oxo)acetic acid 578023-71-9P, [[2-Bromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl] 3-[(trifluoromethoxy)benzyl]amino] (oxo)acetic acid 578023-72-0P, [[2-Bromo-4-[(dodecylamino)carbonyl]benzyl] 3-[(trifluoromethoxy)benzyl]amino] (oxo)acetic acid 578023-73-1P, [[2,6-Dibromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl] 3-[(trifluoromethoxy)benzyl]amino] (oxo)acetic acid 578023-74-2P, [[2,6-Dibromo-4-[(dodecylamino)carbonyl]benzyl] 3-[(trifluoromethoxy)benzyl]amino] (oxo)acetic acid 578023-76-4P, [[2-Bromo-4-[[[(2-(4-phenoxyphenyl)ethyl]amino]carbonyl]benzyl] 4-[(phenoxybenzyl)amino] (oxo)acetic acid 578023-77-5P, [[4-[[[(2,1,1'-Biphenyl)-4-ylethyl]amino]carbonyl]-2-bromobenzyl] 4-[(phenoxybenzyl)amino]glyoxylic acid 578023-78-6P, [[2-Bromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl] 4-[(phenoxybenzyl)amino] (oxo)acetic acid 578023-79-7P, [[2-Bromo-4-[(dodecylamino)carbonyl]benzyl] 4-[(phenoxybenzyl)amino] (oxo)acetic acid 578023-80-0P, [[4-[[[(2,1,1'-Biphenyl)-4-ylethyl]amino]carbonyl]-2,6-dibromobenzyl] 4-[(phenoxybenzyl)amino]glyoxylic acid 578023-81-1P, [[2,6-Dibromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl] 4-[(phenoxybenzyl)amino] (oxo)acetic acid 578023-82-2P, [[4-[[[(2,1,1'-Biphenyl)-4-ylethyl]amino]carbonyl]-2-bromobenzyl] 4-[(trifluoromethoxy)benzyl]amino]glyoxylic acid 578023-83-3P, [[2-Bromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl] 4-[(trifluoromethoxy)benzyl]amino] (oxo)acetic acid 578023-84-4P, [[2-Bromo-4-[(dodecylamino)carbonyl]benzyl] 4-[(trifluoromethoxy)benzyl]amino] (oxo)acetic acid 578023-85-5P, [[2,6-Dibromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl] 4-[(trifluoromethoxy)benzyl]amino] (oxo)acetic acid 578023-86-6P, [[2,6-Dibromo-4-[(dodecylamino)carbonyl]benzyl] 4-[(trifluoromethoxy)benzyl]amino] (oxo)acetic acid 578023-88-8P,

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

[[2-Bromo-4-[(dodecylamino)carbonyl]benzyl] (4-iodobenzyl)amino] (oxo)acetic acid 578023-24-2P, [[2,6-Dibromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl] (4-iodobenzyl)amino] (oxo)acetic acid 578023-26-4P, [[2-Bromo-4-[[[(2-(4-phenoxyphenyl)ethyl]amino]carbonyl]benzyl] [[4'-fluoro-1,1'-biphenyl-3-yl]methyl]amino]glyoxylic acid 578023-27-5P, [[4-[[[(2,1,1'-Biphenyl)-4-ylethyl]amino]carbonyl]-2-bromobenzyl] [[4'-fluoro-1,1'-biphenyl-3-yl]methyl]amino]glyoxylic acid 578023-28-6P, [[2-Bromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl] [[4'-fluoro-1,1'-biphenyl-3-yl]methyl]amino]glyoxylic acid 578023-29-7P, [[2,6-Dibromo-4-[[[(2-(4-phenoxyphenyl)ethyl]amino]carbonyl]benzyl] [[4'-fluoro-1,1'-biphenyl-3-yl]methyl]amino]glyoxylic acid 578023-30-0P,

[[4-[[[(2,1,1'-Biphenyl)-4-ylethyl]amino]carbonyl]-2,6-dibromobenzyl] [[4'-fluoro-1,1'-biphenyl-3-yl]methyl]amino]glyoxylic acid 578023-31-1P

[[2,6-Dibromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl] [[4'-fluoro-1,1'-biphenyl-3-yl]methyl]amino]glyoxylic acid 578023-32-2P,

[[2,6-Dibromo-4-[(dodecylamino)carbonyl]benzyl] [[4'-fluoro-1,1'-biphenyl-3-yl]methyl]amino]glyoxylic acid 578023-35-5P, [[2-Bromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl] 2-[(trifluoromethoxy)benzyl]amino] (oxo)acetic acid 578023-36-6P, [[2,6-Dibromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl] 2-[(trifluoromethoxy)benzyl]amino] (oxo)acetic acid 578023-39-9P, [[2-Bromo-4-[[[(2-(4-phenoxyphenyl)ethyl]amino]carbonyl]benzyl] 3-[(phenoxybenzyl)amino] (oxo)acetic acid 578023-40-2P, [[4-[[[(2,1,1'-Biphenyl)-4-ylethyl]amino]carbonyl]-2-bromobenzyl] 3-[(phenoxybenzyl)amino]glyoxylic acid 578023-41-3P, [[2-Bromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl] 3-[(phenoxybenzyl)amino] (oxo)acetic acid 578023-42-4P, [[2,6-Dibromo-4-[[[(2-(4-phenoxyphenyl)ethyl]amino]carbonyl]benzyl] 3-[(phenoxybenzyl)amino] (oxo)acetic acid 578023-43-5P, [[4-[[[(2,1,1'-Biphenyl)-4-ylethyl]amino]carbonyl]-2,6-dibromobenzyl] 3-[(phenoxybenzyl)amino] (oxo)acetic acid 578023-44-6P, [[2,6-Dibromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl] 3-[(phenoxybenzyl)amino] (oxo)acetic acid 578023-45-7P, [[2,6-Dibromo-4-[(dodecylamino)carbonyl]benzyl] 3-[(phenoxybenzyl)amino] (oxo)acetic acid 578023-49-1P, [[2-Bromo-4-[[[(2-(4-phenoxyphenyl)ethyl]amino]carbonyl]benzyl] 2-iodobenzyl]amino] (oxo)acetic acid 578023-50-4P, [[4-[[[(2,1,1'-Biphenyl)-4-ylethyl]amino]carbonyl]-2-bromobenzyl] 2-iodobenzyl]amino]glyoxylic acid 578023-51-5P, [[2-Bromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl] 2-iodobenzyl]amino] (oxo)acetic acid 578023-52-6P,

[[2-Bromo-4-[(dodecylamino)carbonyl]benzyl] (2-iodobenzyl)amino] (oxo)acetic acid 578023-53-7P, [[2-Bromo-4-[[[(2-(4-phenoxyphenyl)ethyl]amino]carbonyl]benzyl] [[2'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl]amino]glyoxylic acid 578023-54-8P, [[4-[[[(2,1,1'-Biphenyl)-4-ylethyl]amino]carbonyl]-2-bromobenzyl] [[2'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl]amino]glyoxylic acid 578023-55-9P, [[2-Bromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl] [[2'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl]amino]glyoxylic acid

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

[[2-Bromo-4-[(dodecylamino)carbonyl]benzyl] 3-[(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578023-89-9P, [[2,6-Dibromo-4-[(dodecylamino)carbonyl]benzyl] 3-[(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578023-93-5P,

[[4-[(Dodecylamino)carbonyl]benzyl] 1-[[4-(trifluoromethyl)phenyl]ethyl]amino] (oxo)acetic acid 578023-94-6P, [[4-[(Dodecylamino)carbonyl]benzyl] 1-[[4-(trifluoromethyl)phenyl]ethyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578024-00-7P, [(1,2-Diphenylethyl) 4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578024-01-8P, N-(Carboxycarbonyl)-N-4-[(dodecylamino)carbonyl]benzyl]-L-phenylalanine 578024-05-2P, [[4-[(Dodecylamino)carbonyl]benzyl] 3-[(fluoro-4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-08-5P, [[2,4-Dichlorobenzyl] 4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578024-09-6P, [[4-[(Dodecylamino)carbonyl]benzyl] (1-phenylpropyl)amino] (oxo)acetic acid 578024-10-9P,

[[2-(4-Chlorophenyl)propyl] 4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578024-13-2P, [[4-[(Dodecylamino)carbonyl]benzyl] 2-[(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-14-3P, [[4-[(Dodecylamino)carbonyl]benzyl] 2-(methoxybenzyl)amino] (oxo)acetic acid

578024-15-4P, [[[(1R)-1-(4-Chlorophenyl)ethyl] 4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578024-16-5P

[(3,4-Dichlorobenzyl) 4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578024-18-7P, [[2-(2,6-Dichlorophenyl)ethyl] 4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578024-19-8P

[[4-[(Dodecylamino)carbonyl]benzyl] 2-[3-(trifluoromethyl)phenyl]ethyl]amino] (oxo)acetic acid 578024-20-1P, [[4-[(Dodecylamino)carbonyl]benzyl] 1-[2-(3-fluorophenyl)ethyl]amino] (oxo)acetic acid 578024-21-2P, [[[(1S)-1-(4-Chlorophenyl)ethyl] 4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578024-22-3P

[[4-[(Dodecylamino)carbonyl]benzyl] [(1S)-1-phenylethyl]amino] (oxo)acetic acid 578024-23-4P, [[4-[(Dodecylamino)carbonyl]benzyl] [(1R)-1-phenylethyl]amino] (oxo)acetic acid 578024-24-5P, N-(Carboxycarbonyl)-N-4-[(dodecylamino)carbonyl]benzyl]-D-phenylalanine 578024-30-3P, [[1-4-[(Dodecylamino)carbonyl]benzyl] 4-[(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-31-4P, [[1-4-[(Dodecylamino)carbonyl]benzyl] 4-[(trifluoromethyl)benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578024-32-5P, [[4-[[[(4-Octylphenyl)amino]carbonyl]benzyl] 4-[(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-70-1P, [[4-[(Dodecylamino)carbonyl]benzyl] 2-(hydroxy-1-phenylethyl)amino] (oxo)acetic acid 578024-79-0P, [[4-[[[(2-Butylbenzofuran-3-yl)methyl]amino]carbonyl]benzyl] 4-[(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-16-6P,

Oxo[[1-(tridecanoyl)piperidin-4-yl]methyl] 4-[(trifluoromethyl)benzyl]amino]acetic acid 578025-17-9P, [[1-(4-Octylbenzoyl)piperidin-4-yl]methyl] 4-[(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-18-0P, [[1-(4-Octylbenzoyl)piperidin-4-yl]methyl] 4-[(trifluoromethyl)benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578025-86-2P, Benzyl 4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid tromethamine salt 578025-87-3P, [Benzyl 4-

10088060

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

[(dodecylamino)carbonyl]benzyl]amino]oxo]acetic acid

N-methyl-D-glucamine salt 578026-02-5P, [[4-[(dodecylamino)carbonyl]benzyl]([4-(trifluoromethyl)benzyl]amino)oxo]acetic acid N-methyl-D-glucamine salt 578026-05-8P, [[4-[(dodecylamino)carbonyl]benzyl]([3-(trifluoromethyl)benzyl]amino)oxo]acetic acid N-methyl-D-glucamine salt 578029-47-7P, [[4-[(dodecylamino)carbonyl]benzyl]([carboxyphenylmethyl]amino)oxo]acetic acid


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of [(arylmethyl)amino]oxo]acetic acids as PTP inhibitors for antidiabetics)

RN 578021-80-4 CAPLUS


CN Acetic acid,

[[[4-[(dodecylamino)carbonyl]phenyl]methyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)



RN 578021-81-5 CAPLUS

CN Acetic acid, oxo[[[4-[(pentadecylamino)carbonyl]phenyl]methyl]([4-(trifluoromethyl)phenyl]methyl)amino]- (9CI) (CA INDEX NAME)




RN 578021-82-6 CAPLUS

CN Acetic acid,


oxo[[[4-[(pentadecylamino)carbonyl]phenyl]methyl] (phenylmethyl)amino]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 578021-87-1 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl]([4-(trifluoromethyl)phenyl]methyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578021-88-2 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl]([3-(trifluoromethyl)phenyl]methyl)amino]oxo- (9CI) (CA INDEX NAME)



RN 578021-89-3 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-[[[(carboxycarbonyl)]([4-[(dodecylamino)carbonyl]phenyl]methyl)amino]methyl]-, 1-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 578021-99-5 CAPLUS

CN Benzenepropanoic acid, .beta.-[(carboxycarbonyl)]([4-[(dodecylamino)carbonyl]phenyl]methyl)amino]- (9CI) (CA INDEX NAME)


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 578021-83-7 CAPLUS

CN Acetic acid,


oxo[(phenylmethyl)]([4-[(tridecylamino)carbonyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 578021-84-8 CAPLUS

CN Acetic acid,


[[[4-[(dodecylmethylamino)carbonyl]phenyl]methyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)



RN 578021-85-9 CAPLUS

CN Acetic acid, [[4-[(dodecylmethylamino)carbonyl]phenyl]methyl]([4-(trifluoromethyl)phenyl]methyl)amino]oxo- (9CI) (CA INDEX NAME)


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 578022-03-4 CAPLUS


CN Acetic acid,

[[2-(3-chlorophenyl)ethyl]([4-[(dodecylamino)carbonyl]phenyl]methyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-04-5 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl]([2-(3-methoxyphenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578022-10-3 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl]([2-(4-phenoxyphenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-11-4 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl]([2-(2-phenoxyphenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)


Kamal Saeed

10088060


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 578022-12-5 CAPLUS
CN Acetic acid, [[2-[[1,1'-biphenyl]-4-ylethyl][[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578022-13-6 CAPLUS
CN Acetic acid, [[1,1'-biphenyl]-3-ylmethyl][[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-15-8 CAPLUS
CN Acetic acid, [[4-(benzoylamino)phenyl]methyl][[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-16-9 CAPLUS


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 578022-21-6 CAPLUS
CN Acetic acid, [[3-[(dodecylamino)carbonyl]phenyl]methyl][[4-(methylsulfonyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578022-22-7 CAPLUS
CN Acetic acid, [[3-[(dodecylamino)carbonyl]phenyl]methyl][[4-(methylsulfonyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-23-8 CAPLUS
CN Acetic acid, [[3-[(dodecylamino)carbonyl]phenyl]methyl][[4-(methylsulfonyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-24-9 CAPLUS
CN Acetic acid, [[3-[(dodecylamino)carbonyl]phenyl]methyl][[4-(methylsulfonyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

Kamal Saeed


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578022-17-0 CAPLUS
CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-18-1 CAPLUS
CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-20-5 CAPLUS
CN Acetic acid, [[3-[(dodecylamino)carbonyl]phenyl]methyl][[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 578022-25-0 CAPLUS
CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578022-48-7 CAPLUS
CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-49-8 CAPLUS
CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-50-1 CAPLUS
CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

10088060


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 578022-51-2 CAPLUS
 CN Acetic acid, [[3-[(dodecylamino)carbonyl]phenyl]methyl] [[3-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-53-4 CAPLUS
 CN Benzoic acid, 4-[[[(carboxycarbonyl) [[3-[(dodecylamino)carbonyl]phenyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 578022-54-5 CAPLUS
 CN Acetic acid, [[3-[(dodecylamino)carbonyl]phenyl]methyl] [[4-nitrophenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 578022-61-4 CAPLUS
 CN Benzoic acid, 3-[[[(carboxycarbonyl) [[3-[(dodecylamino)carbonyl]phenyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 578022-62-5 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[[[(carboxycarbonyl) [[3-[(dodecylamino)carbonyl]phenyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 578022-63-6 CAPLUS
 CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl] [[4-nitrophenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-65-8 CAPLUS
 CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl] [[2-fluorophenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




Kamal Saeed


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 578022-55-6 CAPLUS
 CN Acetic acid, [[3-[(dodecylamino)carbonyl]phenyl]methyl] [[2-fluorophenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578022-58-9 CAPLUS
 CN Acetic acid, [[3-[(dodecylamino)carbonyl]phenyl]methyl] [[4-hydroxyphenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-59-0 CAPLUS
 CN Acetic acid, [[3-[(dodecylamino)carbonyl]phenyl]methyl] [[4-phenoxyphenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 578022-66-9 CAPLUS
 CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl] [[4-phenoxyphenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-67-0 CAPLUS
 CN Benzoic acid, 4-[[[(carboxycarbonyl) [[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 578022-68-1 CAPLUS
 CN 2-Thiophenecarboxylic acid, 5-[[[(carboxycarbonyl) [[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 578022-71-6 CAPLUS
 CN Acetic acid, [[3-[(dodecylamino)carbonyl]phenyl]methyl] [[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-72-7 CAPLUS
 CN Acetic acid, [[3-[(dodecylamino)carbonyl]phenyl]methyl] [[4-[(3,3-diphenylpropyl)amino]carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

10088060


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
NAME)




RN 578022-73-8 CAPLUS
CN Acetic acid, [[4-[(2-{1,1'-biphenyl}-4-ylethyl)amino]carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578022-78-3 CAPLUS
CN Acetic acid, [[4-[(dimethylamino)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-80-7 CAPLUS
CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-85-2 CAPLUS
CN Acetic acid, [[3-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 578023-11-7 CAPLUS
CN Acetic acid, [[1-[(4-(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-12-8 CAPLUS
CN Acetic acid, [[1-[(4-(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



PAGE 1-A

—NMe2


RN 578023-13-9 CAPLUS
CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-14-0 CAPLUS

Kamal Saeed


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
hydroxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578022-86-3 CAPLUS
CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-93-2 CAPLUS
CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-94-3 CAPLUS
CN Benzoic acid, 3-[[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-15-1 CAPLUS
CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 578023-16-2 CAPLUS
CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-18-4 CAPLUS
CN Acetic acid, [[1-[(3-iodobenzoyl)-4-piperidinyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

10088060

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 578023-19-5 CAPLUS

CN Acetic acid,


oxo[[[1-[(2E)-1-oxo-3-[(trifluoromethyl)phenyl]-2-propenyl]-

4-piperidinyl)methyl][[4-[[[(4-phenoxyphenyl)methyl]amino]carbonyl]phenyl]


methyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



RN 578023-21-9 CAPLUS

CN Acetic acid, [[4-[[[2-[(1,1'-biphenyl)-4-ylethyl]amino]carbonyl]-2-

bromophenyl]methyl][[4-iodophenyl]methyl]amino]oxo- (9CI) (CA INDEX

NAME)

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 578023-26-4 CAPLUS

CN Acetic acid,

[[[2-bromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]phenyl]

methyl][[4'-fluoro[1,1'-biphenyl]-3-yl]methyl]amino]oxo- (9CI) (CA

INDEX NAME)




RN 578023-27-5 CAPLUS

CN Acetic acid, [[4-[[[2-[(1,1'-biphenyl)-4-ylethyl]amino]carbonyl]-2-

bromophenyl]methyl][[4'-fluoro[1,1'-biphenyl]-3-yl]methyl]amino]oxo-

(9CI) (CA INDEX NAME)




RN 578023-28-6 CAPLUS

CN Acetic acid,

[[[2-bromo-4-[[[4-(4-pentylphenyl)methyl]amino]carbonyl]phenyl]

methyl][[4'-fluoro[1,1'-biphenyl]-3-yl]methyl]amino]oxo- (9CI) (CA INDEX

NAME)



PAGE 1-B

—Me

RN 578023-29-7 CAPLUS


CN Acetic acid,

[[[2,6-dibromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]phe-

nyl]methyl][[4'-fluoro[1,1'-biphenyl]-3-yl]methyl]amino]oxo- (9CI) (CA

INDEX NAME)

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 578023-22-0 CAPLUS

CN Acetic acid,

[[[2-bromo-4-[[[4-(4-pentylphenyl)methyl]amino]carbonyl]phenyl]


methyl][[4-iodophenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-23-1 CAPLUS

CN Acetic acid, [[12-bromo-4-[(dodecylamino)carbonyl]phenyl]methyl][[4-

iodophenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-24-2 CAPLUS


CN Acetic acid,

[[[2,6-dibromo-4-[[[4-(4-pentylphenyl)methyl]amino]carbonyl]phe-

nyl]methyl][[4-iodophenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 578023-30-0 CAPLUS

CN Acetic acid, [[4-[[[2-[(1,1'-biphenyl)-4-ylethyl]amino]carbonyl]-2,6-

dibromophenyl]methyl][[4'-fluoro[1,1'-biphenyl]-3-yl]methyl]amino]oxo-

(9CI) (CA INDEX NAME)




RN 578023-31-1 CAPLUS

CN Acetic acid,

[[[2,6-dibromo-4-[[[4-(4-pentylphenyl)methyl]amino]carbonyl]phe-

nyl]methyl][[4'-fluoro[1,1'-biphenyl]-3-yl]methyl]amino]oxo- (9CI) (CA

INDEX NAME)



PAGE 1-A

(CH2)4—

—Me

PAGE 1-B

RN 578023-32-2 CAPLUS


CN Acetic acid, [[12,6-dibromo-4-[(dodecylamino)carbonyl]phenyl]methyl][[4'-

fluoro[1,1'-biphenyl]-3-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)


Kamal Saeed

10088060


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 578023-35-5 CAPLUS
 CN Acetic acid,
 [[2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]
 methyl][2-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX
 NAME)




RN 578023-36-6 CAPLUS
 CN Acetic acid,
 [[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phe
 nyl]methyl][2-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA
 INDEX NAME)




RN 578023-39-9 CAPLUS
 CN Acetic acid,
 [[2-bromo-4-[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]pheny
 l]methyl][(3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 578023-43-5 CAPLUS
 CN Acetic acid, [[4-[[2-[[1,1'-biphenyl]-4-ylethyl]amino]carbonyl]-2,6-
 dibromophenyl]methyl][(3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX
 NAME)



RN 578023-44-6 CAPLUS
 CN Acetic acid,
 [[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phe
 nyl]methyl][(3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-45-7 CAPLUS
 CN Acetic acid, [[2,6-dibromo-4-[(dodecylamino)carbonyl]phenyl]methyl][(3-
 phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




Kamal Saeed


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 578023-40-2 CAPLUS
 CN Acetic acid, [[4-[[2-[[1,1'-biphenyl]-4-ylethyl]amino]carbonyl]-2-
 bromophenyl]methyl][(3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX
 NAME)




RN 578023-41-3 CAPLUS
 CN Acetic acid,
 [[2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]
 methyl][(3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-42-4 CAPLUS
 CN Acetic acid,
 [[2,6-dibromo-4-[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]p
 henyl]methyl][(3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 578023-49-1 CAPLUS
 CN Acetic acid,
 [[2-bromo-4-[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]pheny
 l]methyl][(2-iodophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-50-4 CAPLUS
 CN Acetic acid, [[4-[[2-[[1,1'-biphenyl]-4-ylethyl]amino]carbonyl]-2-
 bromophenyl]methyl][(2-iodophenyl)methyl]amino]oxo- (9CI) (CA INDEX
 NAME)




RN 578023-51-5 CAPLUS
 CN Acetic acid,
 [[2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]
 methyl][(2-iodophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-52-6 CAPLUS
 CN Acetic acid, [[2-bromo-4-[(dodecylamino)carbonyl]phenyl]methyl][(2-
 iodophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)

10088060


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 578023-53-7 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]phenyl]methyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-54-8 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[2-(4-(trifluoromethyl)phenyl)ethyl]amino]carbonyl]phenyl]methyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-55-9 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[2-(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-56-0 CAPLUS


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 578023-61-7 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[2-(4-(trifluoromethyl)phenyl)ethyl]amino]carbonyl]phenyl]methyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-62-8 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[2-(4-(trifluoromethyl)phenyl)ethyl]amino]carbonyl]phenyl]methyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-63-9 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[2-(4-(trifluoromethyl)phenyl)ethyl]amino]carbonyl]phenyl]methyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN Acetic acid, [[2-bromo-4-[[2-(4-(trifluoromethyl)phenyl)ethyl]amino]carbonyl]phenyl]methyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-57-1 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[2-(4-(trifluoromethyl)phenyl)ethyl]amino]carbonyl]phenyl]methyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-58-2 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[2-(4-(trifluoromethyl)phenyl)ethyl]amino]carbonyl]phenyl]methyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-59-3 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[2-(4-(trifluoromethyl)phenyl)ethyl]amino]carbonyl]phenyl]methyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 578023-64-0 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[2-(4-(trifluoromethyl)phenyl)ethyl]amino]carbonyl]phenyl]methyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-65-1 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[2-(4-(trifluoromethyl)phenyl)ethyl]amino]carbonyl]phenyl]methyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-66-2 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[2-(4-(trifluoromethyl)phenyl)ethyl]amino]carbonyl]phenyl]methyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




10088060

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 578023-67-3 CAPLUS
 CN Acetic acid, [[1,1'-biphenyl]-2-ylmethyl][2,6-dibromo-4-(dodecylamino)carbonyl]phenylmethylamino]oxo- (9CI) (CA INDEX NAME)



RN 578023-68-4 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][4-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-69-5 CAPLUS
 CN Acetic acid, [[2-bromo-4-[(dodecylamino)carbonyl]phenyl]methyl][4-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-70-8 CAPLUS
 CN Acetic acid, [[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][4-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


RN 578023-74-2 CAPLUS
 CN Acetic acid, [[2,6-dibromo-4-[(dodecylamino)carbonyl]phenyl]methyl][3-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-76-4 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]phenyl]methyl][4-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-77-5 CAPLUS
 CN Acetic acid, [[4-[[2-[[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][4-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-78-6 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][4-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

Kamal Saeed


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 578023-71-9 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][3-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-72-0 CAPLUS
 CN Acetic acid, [[2-bromo-4-[(dodecylamino)carbonyl]phenyl]methyl][3-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)





RN 578023-73-1 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][3-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 578023-79-7 CAPLUS
 CN Acetic acid, [[2-bromo-4-[(dodecylamino)carbonyl]phenyl]methyl][4-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-81-1 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][4-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




10088060


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RN 578023-82-2 CAPLUS
 CN Acetic acid, [[4-[[[2-(1,1'-biphenyl)-4-ylethyl]amino]carbonyl]-2-bromophenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-83-3 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[[4-(pentyphenyl)methyl]amino]carbonyl]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-84-4 CAPLUS
 CN Acetic acid, [[2-bromo-4-[(dodecylamino)carbonyl]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-85-5 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[[4-(pentyphenyl)methyl]amino]carbonyl]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 578023-93-5 CAPLUS
 CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][1-(4-(trifluoromethyl)phenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-94-6 CAPLUS
 CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[4-[(dodecylamino)carbonyl]phenyl]methyl][1-(4-(trifluoromethyl)phenyl)ethyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 578023-93-5
 CMF C31 H41 F3 N2 O4



CM 2


CRN 6284-40-8
 CMF C7 H17 N O5

Absolute stereochemistry.




Kamal Saeed


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 578023-86-6 CAPLUS
 CN Acetic acid, [[2,6-dibromo-4-[(dodecylamino)carbonyl]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-88-8 CAPLUS
 CN Acetic acid, [[2-bromo-4-[(dodecylamino)carbonyl]phenyl]methyl][3-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-89-9 CAPLUS
 CN Acetic acid, [[2,6-dibromo-4-[(dodecylamino)carbonyl]phenyl]methyl][3-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 578024-00-7 CAPLUS
 CN Acetic acid, [(1,2-diphenylethyl)[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-01-8 CAPLUS
 CN L-Phenylalanine, N-(carboxycarbonyl)-N-[[4-[(dodecylamino)carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 578024-05-2 CAPLUS
 CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][3-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-08-5 CAPLUS
 CN Acetic acid, [[2,4-dichlorophenyl]methyl][4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

10088060


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 578024-09-6 CAPLUS
 CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl] (1-phenylpropyl)amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-10-9 CAPLUS
 CN Acetic acid, [[2-(4-chlorophenyl)propyl] [4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-13-2 CAPLUS
 CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl] [2-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-14-3 CAPLUS


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 578024-19-8 CAPLUS
 CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl] [2-(3-trifluoromethyl)phenyl]ethyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-20-1 CAPLUS
 CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl] [2-(3-fluorophenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-21-2 CAPLUS
 CN Acetic acid, [[(1R)-1-(4-chlorophenyl)ethyl] [4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl] [2-methoxyphenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-15-4 CAPLUS
 CN Acetic acid, [[(1R)-1-(4-chlorophenyl)ethyl] [4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 578024-16-5 CAPLUS
 CN Acetic acid, [[(3,4-dichlorophenyl)methyl] [4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-18-7 CAPLUS
 CN Acetic acid, [[2-(2,6-dichlorophenyl)ethyl] [4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 578024-22-3 CAPLUS
 CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl] [(1S)-1-phenylethyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 578024-23-4 CAPLUS
 CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl] [(1R)-1-phenylethyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 578024-24-5 CAPLUS
 CN D-Phenylalanine, N-(carboxycarbonyl)-N-[[4-[(dodecylamino)carbonyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Kamal Saeed

10088060

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 578024-30-3 CAPLUS
 CN Acetic acid, [[1-[[4-[(dodecylamino)carbonyl]phenyl]ethyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-31-4 CAPLUS
 CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[1-[[4-[(dodecylamino)carbonyl]phenyl]ethyl][4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CH 1

CRN 578024-30-3
 CMF C31 H41 F3 N2 O4




CH 2

CRN 6284-40-8
 CMF C7 H17 N O5


Absolute stereochemistry.

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 578025-16-8 CAPLUS
 CN Acetic acid, oxo[[1-(1-oxotridecyl)-4-piperidinyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-17-9 CAPLUS
 CN Acetic acid, [[1-[[4-(octylbenzoyl)-4-piperidinyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578025-18-0 CAPLUS
 CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[1-[[4-(octylbenzoyl)-4-piperidinyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CH 1


CRN 578025-17-9
 CMF C31 H39 F3 N2 O4




CH 2

CRN 6284-40-8
 CMF C7 H17 N O5


Absolute stereochemistry.




L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 578024-32-5 CAPLUS
 CN Acetic acid, [[4-[[4-(octylphenyl)amino]carbonyl]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-70-1 CAPLUS
 CN Acetic acid, [[4-[[4-(dodecylamino)carbonyl]phenyl]methyl][2-hydroxy-1-phenylethyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-79-0 CAPLUS
 CN Acetic acid, [[4-[[4-(2-butyl-3-benzofuranyl)methyl]amino]carbonyl]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 578025-86-2 CAPLUS
 CN Acetic acid, [[4-[[4-(dodecylamino)carbonyl]phenyl]methyl](phenylmethyl)amino]oxo-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)


CH 1

CRN 578021-80-4
 CMF C29 H40 N2 O4



CH 2


CRN 77-86-1
 CMF C4 H11 N O3



RN 578025-87-3 CAPLUS
 CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[4-[[4-(dodecylamino)carbonyl]phenyl]methyl](phenylmethyl)amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CH 1

CRN 578021-80-4
 CMF C29 H40 N2 O4




Kamal Saeed

10088060

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


CH 2
CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.




RN 578026-02-5 CAPLUS
CN D-Glucitol, 1-deoxy-1-(methylamino)-,
[[[4-[(dodecylamino)carbonyl]phenyl]
methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI)
(CA INDEX NAME)

CH 1
CRN 578021-87-1
CMF C30 H39 F3 N2 O4



CH 2
CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.



RN 578026-05-8 CAPLUS
CN D-Glucitol, 1-deoxy-1-(methylamino)-,
[[[4-[(dodecylamino)carbonyl]phenyl]

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

benzyl ester 578025-84-0P, 4-[[[Benzyl(ethoxyoxalyl)amino]methyl]
benzoic acid 578025-85-1P, Ethyl [benzyl[4-
[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetate 578025-89-5P,
Benzyl
4-[[[ethoxy(oxo)acetyl][4-(trifluoromethyl)benzyl]amino]methyl]benz
oate 578025-90-8P, 4-[[[ethoxy(oxo)acetyl][4-
(trifluoromethyl)benzyl]amino]methyl]benzoic acid 578025-91-9P,
Ethyl oxo[4-(pentadecylamino)carbonyl]benzyl][4-
(trifluoromethyl)benzyl]amino]acetate 578025-92-0P, Ethyl
[benzyl[4-(pentadecylamino)carbonyl]benzyl]amino] (oxo)acetate
578025-93-1P, Ethyl [benzyl[4-(tridecylamino)carbonyl]benzyl]amin
o] (oxo)acetate 578025-94-2P, Ethyl [benzyl[4-
[(dodecyl(methyl)amino)carbonyl]benzyl]amino] (oxo)acetate
578025-95-3P, Ethyl [[4-[(dodecyl(methyl)amino)carbonyl]benzyl][4-
(trifluoromethyl)benzyl]amino] (oxo)acetate 578026-01-4P, Ethyl

[[4-[(dodecylamino)carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo) a
cetate 578026-04-7P, Ethyl [[4-[(dodecylamino)carbonyl]benzyl][3-
(trifluoromethyl)benzyl]amino] (oxo)acetate 578026-07-0P,
tert-Butyl 4-[[[4-[(dodecylamino)carbonyl]phenyl]methyl][2-ethoxy-2-
(oxo)acetyl]amino]methyl]piperidine-1-carboxylate 578026-44-5DP,
Ethyl [benzyl[3-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetate,
resin-bound 578026-51-4P, tert-Butyl 4-[[[4-
(benzyloxy)carbonyl]phenyl]methyl][2-ethoxy-2-
(oxo)acetyl]amino]methyl]piperidine-1-carboxylate 578026-52-5P,
4-[[[1-(tert-Butoxycarbonyl)piperidin-4-yl]methyl][2-ethoxy-2-
(oxo)acetyl]amino]methyl]benzoic acid 578026-54-7P,
4-[[[N-[2-ethoxy-2-(oxo)acetyl]-N-[1-(9H-fluoren-9-
ylmethoxy)carbonyl]piperidin-4-yl]methyl]amino]methyl]benzoic acid
578026-55-8DP, 9H-Fluoren-9-ylmethyl 4-[[[4-
(dodecylamino)carbonyl]phenyl]methyl][2-ethoxy-2-
(oxo)acetyl]amino]methyl]piperidine-1-carboxylate, resin-bound
578026-57-0DP, Ethyl [[1-[(cyclohexylamino)carbonyl]piperidin-4-
yl]methyl][4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetate,
resin-bound 578026-77-4P, Ethyl [[4-

[(dodecylamino)carbonyl]benzyl][1-[(4-(trifluoromethyl)phenyl)ethyl]amino] (

oxo)acetate 578027-03-9P, Ethyl [[1-4-

[(dodecylamino)carbonyl]phenyl]ethyl][4-(trifluoromethyl)benzyl]amino] (oxo

acetate 578027-04-9P, Ethyl [[4-[[4-

octylphenyl]amino]carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo) ac

etate 578027-78-8P, Ethyl [[4-[[[2-butylbenzofuran-3-

yl]methyl]amino]carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo) acet

ate 578028-21-4P, tert-Butyl 4-[[[2-(2-ethoxy-2-(oxo)acetyl][4-

(trifluoromethyl)benzyl]amino]methyl]piperidine-1-carboxylate

578028-23-6P, Ethyl oxo[[1-(tridecanoyl)piperidin-4-yl]methyl][4-

(trifluoromethyl)benzyl]amino]acetate 578028-24-7P, Ethyl

[[1-[(4-octylbenzoyl)piperidin-4-yl]methyl][4-

(trifluoromethyl)benzyl]amino] (oxo)acetate

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(Intermediate; prepn. of [arylmethyl]amino] (oxo)acetic acids as PTP

inhibitors for antidiabetics)

RN 578028-20-5 CAPLUS


CN Acetic acid,

[[[3-[(dodecylamino)carbonyl]phenyl]methyl] (phenylmethyl)amin

Kamal Saeed


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

CH 1
CRN 578021-88-2
CMF C30 H39 F3 N2 O4




CH 2
CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.




RN 578029-47-7 CAPLUS
CN Benzenecetic acid, .alpha.-[[[carboxycarbonyl][4-
[(dodecylamino)carbonyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




IT 578022-20-5DP, [Benzyl[3-[(dodecylamino)carbonyl]benzyl]amino] (oxo
)acetic acid, resin-bound 578023-11-7DP, [[1-
[(cyclohexylamino)carbonyl]-4-piperidinyl]methyl]-N-[4-
[(dodecylamino)carbonyl]benzyl]amino]glyoxylic acid, resin-bound
578025-83-9P, 4-[[[Benzyl(ethoxyoxalyl)amino]methyl]benzoic acid

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


o]oxo- (9CI) (CA INDEX NAME)




RN 578023-11-7 CAPLUS
CN Acetic acid, [[1-[(cyclohexylamino)carbonyl]-4-piperidinyl]methyl][4-
[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578025-83-9 CAPLUS
CN Benzoic acid, 4-[[[ethoxyoxoacetyl] (phenylmethyl)amino]methyl]-,
phenylmethyl ester (9CI) (CA INDEX NAME)




RN 578025-84-0 CAPLUS
CN Benzoic acid, 4-[[[ethoxyoxoacetyl] (phenylmethyl)amino]methyl]- (9CI)
(CA INDEX NAME)




RN 578025-85-1 CAPLUS
CN Acetic acid,
[[[4-[(dodecylamino)carbonyl]phenyl]methyl] (phenylmethyl)amin
o]oxo-, ethyl ester (9CI) (CA INDEX NAME)

10088060


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 578025-89-5 CAPLUS
CN Benzoic acid,
4-[[4-[(ethoxyoxoacetyl)[(4-(trifluoromethyl)phenyl)methyl]amino]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 578025-90-8 CAPLUS
CN Benzoic acid,
4-[[4-[(ethoxyoxoacetyl)[(4-(trifluoromethyl)phenyl)methyl]amino]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 578025-91-9 CAPLUS
CN Acetic acid, oxo[[4-[(pentadecylamino)carbonyl]phenyl)methyl][4-(trifluoromethyl)phenyl)methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578025-92-0 CAPLUS
CN Acetic acid,
oxo[[4-[(pentadecylamino)carbonyl]phenyl)methyl](phenylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 578026-01-4 CAPLUS
CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl)methyl][4-(trifluoromethyl)phenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 578026-04-7 CAPLUS
CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl)methyl][3-(trifluoromethyl)phenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578026-07-0 CAPLUS
CN 1-Piperidinecarboxylic acid,
4-[[4-[(dodecylamino)carbonyl]phenyl)methyl][3-(trifluoromethyl)phenyl)methyl]amino]oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 578026-44-5 CAPLUS
CN Acetic acid,
[[4-[(dodecylamino)carbonyl]phenyl)methyl](phenylmethyl)amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)

Kamal Saeed


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 578025-93-1 CAPLUS
CN Acetic acid,
oxo[[4-[(tridecylamino)carbonyl]phenyl)methyl](phenylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578025-94-2 CAPLUS
CN Acetic acid,
[[4-[(dodecylamino)carbonyl]phenyl)methyl](phenylmethyl)amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578025-95-3 CAPLUS
CN Acetic acid, [[4-[(dodecylmethylamino)carbonyl]phenyl)methyl][4-(trifluoromethyl)phenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 578026-51-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[4-[(ethoxyoxoacetyl)[(4-(phenylmethoxy)carbonyl]phenyl)methyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 578026-52-5 CAPLUS
CN 1-Piperidinecarboxylic acid,
4-[[4-[(4-carboxyphenyl)methyl](ethoxyoxoacetyl)amino]methyl]-, 1-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 578026-54-7 CAPLUS
CN 1-Piperidinecarboxylic acid,
4-[[4-[(4-carboxyphenyl)methyl](ethoxyoxoacetyl)amino]methyl]-, 1-(9H-fluoren-9-ylmethyl) ester (9CI) (CA INDEX NAME)


10088060

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 578026-55-8 CAPLUS
CN 1-Piperidinecarboxylic acid,
4-[[[4-[(dodecylamino)carbonyl]phenyl]methyl
(ethoxycarbonyl)amino]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA
INDEX NAME)

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 578026-57-0 CAPLUS
CN Acetic acid, [[1-[(cyclohexylamino)carbonyl]-4-piperidinyl]methyl][4-
[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA
INDEX NAME)


L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 578026-77-4 CAPLUS
CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][1-[(4-
(trifluoromethyl)phenyl)ethyl]amino]oxo-, ethyl ester (9CI) (CA INDEX
NAME)



RN 578027-03-9 CAPLUS
CN Acetic acid, [[1-[(4-[(dodecylamino)carbonyl]phenyl)ethyl][4-
(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX
NAME)



RN 578027-04-0 CAPLUS
CN Acetic acid, [[4-[(4-octylphenyl)amino]carbonyl]phenyl]methyl][4-
(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX
NAME)




RN 578027-78-8 CAPLUS


Kamal Saeed

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


CN Acetic acid,
[[[4-[[[(2-butyl-3-benzofuranyl)methyl]amino]carbonyl]phenyl]
methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI)
(CA INDEX NAME)




RN 578028-21-4 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[ethoxycarbonyl][4-
(trifluoromethyl)phenyl]methyl]amino]methyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)



RN 578028-23-6 CAPLUS
CN Acetic acid, oxo[[[1-(1-oxotridecyl)-4-piperidinyl]methyl][4-
(trifluoromethyl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX
NAME)



RN 578028-24-7 CAPLUS
CN Acetic acid, [[1-[(4-octylbenzoyl)-4-piperidinyl]methyl][4-
(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX
NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

10088060

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

L3 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:511319 CAPLUS
 DOCUMENT NUMBER: 139:85380
 TITLE: Preparation of benzhydryl-substituted piperazine derivatives as tachykinin antagonists
 INVENTOR(S): Take, Kazuhiko; Kasahara, Chiyoshi; Shigenaga, Shinji;
 PATENT ASSIGNEE(S): Eisai, Yoshiteru; Tojo, Takashi
 SOURCE: Fujisawa Pharmaceutical Co., Ltd., USA
 PCT Int. Appl., 167 pp.
 CODEN: PIXXDZ
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003053957	A1	20030703	WO 2002-JP13156	20021216
W:	AF, AG, AI, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TE, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPL. INFO.:		AU 2001-9707	A	20011221
OTHER SOURCE(S):		MARPAT 139:85380		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [R1-2 = H, halo, alkyl; R3-5 = H, halo, (cyclo)alkyl, alkoxy; R6 = H, alkyl] are prep'd. For instance, 2-[(6R,9aR)-6-benzhydryloctahydro-2H-pyrazino[1,2-a]pyrazin-2-yl]-2-oxoethanol (prepn. given) is reacted with 2,4,6-trimethoxy-5-pyrimidinecarboxaldehyde (prepn. given; CH2Cl2, NaBH(OAc)3) to give II. Example compds. at 1 mg/kg showed 100% inhibition of emesis in a dog model. I are tachykinin antagonists and are useful for treating or preventing tachykinin-mediated diseases.

IT 552880-61-2P, (2R)-4-(Benzyloxycarbonyl)-1-(tert-butoxycarbonyl)-2-[[N-[3,3-bis(4-fluorophenyl)-2-oxopropyl]-N-(2-methoxybenzyl)amino]methyl]piperazine 552880-62-3P, (2R)-4-(Benzyloxycarbonyl)-1-(tert-butoxycarbonyl)-2-[[N-[3,3-bis(4-methylphenyl)-2-oxopropyl]-N-(2-methoxybenzyl)amino]methyl]piperazine RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or Reagent) (prepn. of benzhydryl-substituted piperazine derivs. as tachykinin antagonists)

RN 552880-61-2 CAPLUS


L3 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN 1,4-Piperazinedicarboxylic acid, 2-[[[3,3-bis(4-fluorophenyl)-2-oxopropyl][(2-methoxyphenyl)methyl]amino]methyl]-, 1-(1,1-dimethylethyl) 4-(phenylmethyl) ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 552880-62-3 CAPLUS
 CN 1,4-Piperazinedicarboxylic acid, 2-[[[3,3-bis(4-methylphenyl)-2-oxopropyl][(2-methoxyphenyl)methyl]amino]methyl]-, 1-(1,1-dimethylethyl) 4-(phenylmethyl) ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.


FORMAT

L3 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:509785 CAPLUS
 DOCUMENT NUMBER: 140:164189
 TITLE: Cyclolinopeptide A analogues containing N-benzylglycine as a peptoid building block
 AUTHOR(S): Leplawy, Mirosław T.; Zubrzak, Paweł; Olejniczak, Bogdan; Faneth, Piotr; Smoluch, Marek; Silberring, Jerzy; Kowalski, Marek L.; Szudłowska, Barbara; Grochulska, Ewa; Zabrocki, Janusz
 CORPORATE SOURCE: Institute of Organic Chemistry, Technical University, Łódź, 90-924, Pol.
 SOURCE: Peptides 2000, Proceedings of the European Peptide Symposium, 26th, Montpellier, France, Sept. 10-15, 2000 (2001), Meeting Date 2000, 859-860. Editor(s): Martinez, Jean; Fehrentz, Jean-Alain. Editions EDK: Paris, Fr.
 CODEN: 69EDMK; ISBN: 2-84254-048-4
 DOCUMENT TYPE: Conference
 LANGUAGE: English
 AB A symposium report. Linear and cyclic cyclolinopeptide A analogs containing N-benzylglycine in positions 8 and 9 were synthesized by SPPS technique, followed by cyclization. Four compds. were tested for immunosuppressive activity. Conformational search for studied peptides was carried out using random variation of four dihedral angles using MM+ and Amber 6 force fields.
 IT 655251-37-9P
 RI: BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (solid phase synthesis of linear and cyclic cyclolinopeptide A analogs, their immunosuppressive activity and conformation)
 RN 655251-37-9 CAPLUS
 CN Glycine, L-leucyl-L-isoleucyl-L-isoleucyl-L-leucyl-L-valyl-L-prolyl-L-prolyl-N-(phenylmethyl)glycyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

Kamal Saeed

10088060

L3 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



IT 655251-36-8P
 RL: BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(solid phase synthesis of linear and cyclic cyclolinopeptide A

analogs, their immunosuppressive activity and conformation)


RN 655251-36-8 CAPLUS

CN L-Phenylalanine, L-leucyl-L-isoleucyl-L-isoleucyl-L-leucyl-L-valyl-L-prolyl-L-prolyl-N-(phenylmethyl)glycyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L3 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)

PAGE 1-A



PAGE 2-A




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN

ACCESSION NUMBER: 2003:154392 CAPLUS
 DOCUMENT NUMBER: 138:205074
 TITLE: Preparation of .beta.-ketoamide compounds as HIV integrase inhibitors
 INVENTOR(S): Katoh, Susumu; Miyazaki, Susumu; Habuka, Noriyuki
 PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan
 SOURCE: PCT Int. Appl., 252 pp.
 CODEN: PIYXMD
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003016266	A1	20030227	WO 2002-JP8211	20020812
<p>W: AZ, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZH, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p>				
<p>TH: RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG</p>				
JP 2004043416	A2	20040212	JP 2002-236737	20020815
<p>PRIORITY APPLN. INFO.: JP 2001-247346 A 20010816 JP 2001-372066 A 20011205 JP 2002-151232 A 20020524</p>				
<p>OTHER SOURCE(S): HARPAT 138:205074</p>				
<p>GI</p>				



AB .beta.-Ketoamide compds. represented by the following general formula (I) or pharmaceutically acceptable salts thereof[the ring A = (un)substituted C3-10 carbocyclic group, (un)substituted heterocyclyl optionally contg.

at least one heteroatoms selected from N, O, and S; X = a bond, Cl-6 alkylene, C2-6 alkenylene, (CH2)m-2, (CH2)n-2 [wherein Z = O, (un)substituted NH, CO, SO, SO2; m = an integer of 0-4; n = an integer of 1-4; * denotes an ending which is bonded to the N atom of .beta.-ketoamide]; R1 = Cl-10 alkyl, C2-10 alkenyl, Q (wherein Y and the ring B are same or different groups defined in X and the ring A, resp.); R2 = CO2R5, CONR6R7, COR8, (un)substituted heterocyclyl (wherein R5-R8 = H, (un)substituted Cl-10 alkyl, C3-10 carbocyclyl, or heterocyclyl); R3 = H, halo, Cl-4 alkyl, Cl-4 alkoxy, COR9, O-COR9, CONR10R11 [R9-R11 = H, (un)substituted Cl-10 alkyl or C3-10 carbocyclyl]; provided that .beta.-oxo-N,N-bis(phenylmethyl)-2-thiophenepropanamide is excluded] are prepd. and anti-HIV agents contg. these compds. I are claimed. Because

Kamal Saeed

L3 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 having an HIV integrase inhibitory activity, the above compds. I are useful as anti-HIV agents to be used in remedies or preventives for AIDS. Further efficacious anti-HIV agents can be obtained by combining the compds. with other anti-HIV agents such as a protease inhibitor or a reverse transcriptase inhibitor. Because of showing a specifically high inhibitory activity on integrase, these compds. I are usable as safe drugs

with little side effects on the human body. Thus, 3.5 g N-(3-carboxyphenyl)-N-(3,4-dichlorobenzyl)acetamide (prepn. given) was dissolved in 105 mL THF, cooled in a dry ice-ethanol bath, treated dropwise with 5.2 mL 1.5 M lithium diisopropylamide/cyclohexane, stirred for 15 min at the same temp., treated dropwise with a soln. of 2.6 g Me 2,2,5,5-tetramethylcyclopentyl oxalate in 10 mL THF, stirred for 15 min

at the same temp., and warmed to room temp. and stirred at room temp. for 3

h to give 1.42 g 2,2,5,5-tetramethylcyclopentyl 4-[N-(3-carboxyphenyl)-N-(3,4-dichlorobenzyl)amino]-2,4-dioxobutanoate (II). II, 2,2,5,5-tetramethylcyclopentyl 4-[N-(3-carboxy-3-methoxyphenyl)-N-(3,4-dichlorobenzyl)amino]-2,4-dioxobutanoate, and


N-(3,4-dichlorobenzyl)-N-(3-chloro-4-carboxyphenyl)-3-(4-methoxypyrimidin-2-yl)-3-oxopropanamide showed IC50 of 0.0092, 0.0041, and 0.0072 .mu.M, resp., against recombinant HIV integrase.

IT 500159-69-3P 500159-73-9P 500159-81-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of .beta.-ketoamide compds. as HIV integrase inhibitors and anti-HIV agents for treatment or prevention of AIDS)


RN 500159-69-3 CAPLUS
 CN Benzoic acid, 3-[[[(3,4-dichlorophenyl)methyl][1,3-dioxo-3-(2-pyrimidinyl)propyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 500159-73-9 CAPLUS
 CN 2-Pyrimidinepropanamide, N-[(3,4-dichlorophenyl)methyl]-N-[[3-[[dimethylamino]carbonyl]phenyl]methyl]-.beta.-oxo- (9CI) (CA INDEX NAME)

10088060

L3 ANSWER 10 OF 16 CAPIUS COPYRIGHT 2004 ACS on STN (Continued)




RN 500159-81-9 CAPIUS
 CN Benzoic acid,
 3-[[[(3,4-dichlorophenyl)methyl][3-(4-methoxy-2-pyrimidinyl)-
 1,3-dioxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L3 ANSWER 11 OF 16 CAPIUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:132088 CAPIUS
 DOCUMENT NUMBER: 139:85623
 TITLE: Via Ugi reactions to conformationally fixed cyclic
 peptides
 AUTHOR(S): Hebach, Christina; Kozmaier, Ull
 CORPORATE SOURCE: Institut für Organische Chemie, Universität des
 Saarlandes, Saarbrücken, D-66123, Germany
 SOURCE: Chemical Communications (Cambridge, United Kingdom)
 (2003), (5), 596-597
 CODEN: CHCOFS; ISSN: 1359-7345
 PUBLISHER: Royal Society of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 139:85623
 GI



AB A simple approach to several cyclic peptidomimetics (e.g., I) contg. an
 N-alkylated amino acid was found via a multicomponent reaction followed
 by
 a ring-closing metathesis starting from readily available precursors.
 The
 combinatorial technique has the advantage that different polar,
 hydrophilic or hydrophobic moieties can be placed at any position in the
 cycles and unnatural amino acids can also be incorporated.
 IT 553636-72-99
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. of cyclic oligopeptides via 4-component Ugi and ring-closing
 metathesis reactions)
 RN 553636-72-9 CAPIUS
 CN Glycine, 1-[(2-propenyloxy)carbonyl]-L-prolyl-N-[(1S)-1-(3-
 methoxyphenyl)ethyl]-L-valyl-, 2-propenyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L3 ANSWER 11 OF 16 CAPIUS COPYRIGHT 2004 ACS on STN (Continued)




REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR
 THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L3 ANSWER 12 OF 16 CAPIUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2002:964356 CAPIUS
 DOCUMENT NUMBER: 138:39303
 TITLE: Preparation of fused-ring diazepines, method of
 preparation and use as anti-bacterial agents
 INVENTOR(S): Azodi, Joseph; Lampilas, Maxime; Musicki, Branislav;
 Rowlands, David Alan; Collette, Pascal
 PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr.
 SOURCE: PCT Int. Appl., 224 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100860	A2	20021219	WO 2002-FR1877	20020604
WO 2002100860	A3	20031120		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2825705	A1	20021213	FR 2001-7520	20010608
EP 1399444	A2	20040324	EP 2002-778894	20020604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.: FR 2001-7520 A 20010608 WO 2002-FR1877 W 20020604				

OTHER SOURCE(S): MARPAT 138:39303
 GI




AB The invention concerns novel heterocyclic compds. (shown as I; variables
 defined below: e.g. 3-benzoyl-1,3,4,5-tetrahydro-1,4-methano-2H-1,3-
 benzodiazepin-2-one), and their addn. salts with a base or an acid. The
 invention also concerns a method for prep. I, and their use as
 medicines,
 in particular as antibacterial agents. For I: (a) R1 = H, COOH, CN,
 COOR,
 (CH2)n'R5, CONR6, R7 or C(NR6)NHR7; R = alkyl contg. 1-6 atoms of C,
 optionally substituted by pyridyl, a -CH2-alkenyl radical contg. 3-9
 atoms
 of C, (poly)alkoxyalkyl contg. 1-4 atoms of O and 3-10 atoms of C, aryl
 with 6-10 atoms of C or aralkyl contg. 7-11 atoms of C, the nucleus of
 the

Kamal Saeed

10088060

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
aryl or aralkyl being optionally substituted by OH, NH₂, NO₂, alkyl
contg.
1-6 atoms of C, alkoxy contg. 1-6 atoms of C or by .gtoreq.1 atoms of
halogen. R₅ = COOH, CN, OH, NH₂, CONH₂, CO₂R, OR, OCOH, OCO₂R,
OCO₂NR, OCONH₂, OSO₂R, NHR, NHCOR, NHCOR, NHCOR, NHCOR, NHCOR, NHCOR,
NH-CO-NH₂ or N₃; R₆ and R₇, same or different, = H, alkyl contg. 1-6
atoms
of C, aryl contg. 6-10 atoms of C and aralkyl contg. 7-11 atoms of C and
alkyl contg. 1-6 atoms of C substituted by pyridyl; n' = 1 or 2, R₃ and
R₄
together form a Ph or a heterocycle with arom. character with 5 or 6
vertices contg. 1-4 heteroatoms = N, O and S, and optionally substituted
by .gtoreq.1 groups R', R' being = H and alkyl contg. 1-6 atoms of C
optionally substituted by .gtoreq.1 radicals hydroxy, oxo, halogen, or
cyano or by a radical nitro, alkenyl contg. 2-6 atoms of C, halo, amino,
OH, protected OH, -OR, -NHCOR, - NHCOR, NHCOR, COOH, COOR, -CPH₃ and
-CH₂CH₂(O)mR and m = 0, 1 or 2; (b) R₄ = H or (CH₂)n'1R₅, n'1 = 0, 1
or
2, and R₁ and R₃ together form a Ph or a heterocycle optionally
substituted. In the 2 cases (a) and (b) R₂ = H, halo and R, S(O)mR, OR,
NHCOR, NHCOR and NHCOR; X = divalent -C(O)-S- bound to N by C atom; B =
divalent -O-(CH₂)n''- bound to carbonyl by O, -NR₈-(CH₂)n''- or -NR₈-O-
bound to carbonyl by N; n'' = 0 or 1 and R₈ = H, OH, R, OR, Y, OY, Y1,
OY1, Y2, OY2, Y3, O-CH₂-CH₂-S(O)m-R, SiR_aR_bR_c and OSiR_aR_bR_c, R_a, R_b and
R_c
representing individually linear or branched alkyl contg. 1-6 atoms of C
or aryl contg. 6-10 atoms of C; Y = COH, CO₂R, COOR, CONH₂, CONHR, CONHOH,
CONHSO₂R, CH₂COOH, CH₂COOR, CH₂CONH₂, CH₂CONHR, CH₂CONHOH, protected
CH₂tetrazole, CH₂SO₂H, CH₂SO₂R, CH₂PO(OH)₂, CH₂PO(OH)(OR), CH₂PO(OH)(OR)
and CH₂PO(OH)₂. Y1 = SO₂R, SO₂NHCOH, SO₂NHCOR, SO₂NHCOOR, SO₂NHCONHR,
SO₂NHCONH₂ and SO₃H; Y2 = PO(OH)₂, PO(OH)₂, PO(OH)(OR) and PO(OH)(R); Y3
=
tetrazole, tetrazole substituted by radical R, squarate, NH or NR
tetrazole, NH or NR tetrazole substituted by radical R, NHCOR and
NHCOR;
n = 1 or 2. Sixty-eight example preps. are included. For example,
3-benzoyl-1,3,4,5-tetrahydro-1,4-methano-2H-1,3-benzodiazepin-2-one was
prepd. in 2 steps comprising treatment of N-(1,2,3,4-tetrahydro-3-
quinolinyl)benzamide in CH₂Cl₂ with Et₃N followed by diphenyl ether in the
1st
step (76 %) followed by addn. of LiN(SiMe₃)₂ in THF to the intermediate
(63 %). Eleven I were tested for antibacterial activity against 3
gram-pos. and 3 gram-neg. bacteria and the results are tabulated in
ranges.
IT 478628-37-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. of fused-ring diazepines, method of prepn. and use as
anti-bacterial agents)
RN 478628-37-4 CAPLUS
CN 3-Pyridinecarboxylic acid, 2-[[[2-(1,1-dimethylethoxy)-2-
oxoethyl](phenylmethyl)amino]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




L3 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:695933 CAPLUS
DOCUMENT NUMBER: 137:232445
TITLE: Preparation of aminodicarboxylic acids for the
treatment of cardiovascular diseases
INVENTOR(S): Alonso-Alija, Cristina; Haerter, Michael; Hahn,
Michael; Pernertorfer, Josef; Weigand, Stefan;
Stasch, Johannes-Peter; Wunder, Frank
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 162 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002070462	A1	20020912	WO 2002-EP1941	20020225
W: AZ, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MO, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG				
DE 10110749	A1	20020912	DE 2001-10110749	20010307
EP 1368300	A1	20031210	EP 2002-703602	20020225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.: DE 2001-10110749 A 20010307 WO 2002-EP1941 W 20020225				
OTHER SOURCE(S): MARPAT 137:232445				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [V = absent, O, COO, etc.; Q = absent, (un)substituted alkylene, alkendyl, etc.; Y = H, NR₈R₉, (un)substituted aryl, etc.; W = (un)substituted alkylene, alkendyl; U = (un)substituted alkyl; A = (un)substituted aryl, heteroatom. contg. 1-3 heteroatoms, e.g., S, N, O;
X = (un)substituted alkylene, alkendyl, aryl, etc.; R₁ = tetrazolyl, COOR₃, CONR₃IR₃; R₂ = tetrazolyl, COOR₂, CONR₂SR₂, R₂5 and R₂6 form
S or 6-membered ring which can be interrupted by O or N; R₃ = aryl, SR₁7, SO₂R₁7, etc.; R₈, R₉, R₁7 = H, (un)substituted alkyl, alkenyl, etc.; R₂4
= H, (un)substituted alkyl, cycloalkyl; R₂5, R₂6 = H, (un)substituted alkyl, cycloalkyl, etc.; R₃0 = H, (un)substituted alkyl, cycloalkyl; R₃1, R₃2 = H, (un)substituted alkyl, cycloalkyl, etc.; m = 1-4; n = 1-2] and their pharmaceutically acceptable salts were prepd. For example, Pd(Ph)₃2Cl₂ mediated coupling of aryl bromide II, prepd. from ethyl-2-hydroxy-5-

L3 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
trifluoromethoxybenzoate in 8-steps, with 4-chlorophenyl boronic acid, followed by ester hydrolysis afforded aminodicarboxylate III. Compds. I stimulated the activation of sol. guanylate cyclase (sGC) independent of the heme group (no data).
IT 457889-53-1P 457889-54-2P 457889-70-2P 457889-72-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of aminodicarboxylic acids for the treatment of cardiovascular diseases via the activation of sol. guanylate cyclase (sGC))
RN 457889-53-1 CAPLUS
CN Benzoic acid,
4-[[[2-[4-[(4-cyclohexylphenyl)methoxy]-2',4'-difluoro[1,1'-biphenyl]-3-yl]ethyl](5-methoxy-5-oxopentyl)amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 457889-54-2 CAPLUS
CN Benzoic acid, 4-[[[2-[2',4'-difluoro-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy][1,1'-biphenyl]-3-yl]ethyl](5-methoxy-5-oxopentyl)amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Kamal Saeed

10088060

L3 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 457889-70-2 CAPLUS
 CN Benzoic acid, 4-[[[2-[2-[(4-bromophenyl)methoxy]-5-(trifluoromethoxy)phenyl]ethyl] (5-ethoxy-5-oxopentyl)amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 457889-72-4 CAPLUS
 CN Benzoic acid, 4-[[[2-[2-[(4-chlorophenyl)methoxy]-5-(trifluoromethoxy)phenyl]ethyl] (5-ethoxy-5-oxopentyl)amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl) [2-[2',4'-difluoro-4-[[4'-(trifluoromethyl) [1,1'-biphenyl]-4-yl]methoxy] [1,1'-biphenyl]-3-yl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 457889-15-5 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl) [2-[2-[(4'-chloro[1,1'-biphenyl]-4-yl]methoxy]-5-(trifluoromethoxy)phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 457889-17-7 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl) [2-[2-[(3',5'-dichloro[1,1'-biphenyl]-4-yl]methoxy]-5-(trifluoromethoxy)phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



IT 457889-11-1P 457889-13-3P 457889-15-5P
 457889-17-7P 457889-19-9P 457889-21-3P
 457889-23-5P 457889-25-7P 457889-27-9P
 457889-29-1P 457889-31-5P 457889-33-7P
 457889-35-9P 457889-37-1P 457889-39-3P
 457889-41-7P 457889-42-8P 457889-43-9P
 457889-44-0P 457889-45-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (target compd.; prepn. of aminodicarboxylic acids for the treatment of cardiovascular diseases via the activation of sol. guanylate cyclase (5GC))

RN 457889-11-1 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl) [2-[4-[(4-cyclohexylphenyl)methoxy]-2',4'-difluoro[1,1'-biphenyl]-3-yl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 457889-13-3 CAPLUS


L3 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 457889-19-9 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl) [2-[2-[(4'-methoxy[1,1'-biphenyl]-4-yl]methoxy]-5-(trifluoromethoxy)phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 457889-21-3 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl) [2-[2-[(4'-methylthio[1,1'-biphenyl]-4-yl]methoxy]-5-(trifluoromethoxy)phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 457889-23-5 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl) [2-[2-[(2',4'-dichloro[1,1'-biphenyl]-4-yl]methoxy]-5-(trifluoromethoxy)phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

10088060


L3 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 457889-25-7 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl) [2-[2-[(3'-methoxy[1,1'-biphenyl]-4-yl)methoxy]-5-(trifluoromethoxy)phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 457889-27-9 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl) [2-[2-[(3',4'-dichloro[1,1'-biphenyl]-4-yl)methoxy]-5-(trifluoromethoxy)phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 457889-29-1 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl) [2-[2-[(3-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)methoxy]-5-(trifluoromethoxy)phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 457889-37-1 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl) [2-[2-[(3'-fluoro[1,1'-biphenyl]-4-yl)methoxy]-5-(trifluoromethoxy)phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 457889-39-3 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl) [2-[2-[(3'-chloro-2'-methyl[1,1'-biphenyl]-4-yl)methoxy]-5-(trifluoromethoxy)phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 457889-41-7 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl) [2-[2-[(3-chloro[1,1'-biphenyl]-4-yl)methoxy]-5-(trifluoromethoxy)phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 457889-31-5 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl) [2-[2-[(3',5'-difluoro[1,1'-biphenyl]-4-yl)methoxy]-5-(trifluoromethoxy)phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 457889-33-7 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl) [2-[2-[(3',5'-difluoro[1,1'-biphenyl]-4-yl)methoxy]-5-(trifluoromethoxy)phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 457889-35-9 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl) [2-[2-[(2',4'-difluoro[1,1'-biphenyl]-4-yl)methoxy]-5-(trifluoromethoxy)phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 457889-42-8 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl) [2-[2-[(4'-chloro-2'-methyl[1,1'-biphenyl]-4-yl)methoxy]-5-(trifluoromethoxy)phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 457889-43-9 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl) [2-[2-[(2',3'-dichloro[1,1'-biphenyl]-4-yl)methoxy]-5-(trifluoromethoxy)phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)





RN 457889-44-0 CAPLUS


Kamal Saeed

10088060

L3 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)[2-[2-[[5'-fluoro-2'-methyl[1,1'-biphenyl]-4-yl)methoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 457889-45-1 CAPLUS
 CN Benzoic acid, 4-[[[2-[2-[[4-bromophenyl)methoxy]-5-(trifluoromethoxy)phenyl]ethyl](4-carboxybutyl)amino]methyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.
 FORMAT

L3 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; prepn. of aminodicarboxylic acids for the treatment

of cardiovascular diseases via the activation of sol. guanylate cyclase (sGC))

RN 454465-61-3 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)[2-[2-[[3-fluoro-4'-methoxy[1,1'-biphenyl]-4-yl)methoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




IT 454465-59-9P 454465-60-2P 454465-62-4P
 454465-63-5P 454465-64-6P 454465-65-7P
 454465-66-8P 454465-67-9P 454465-68-0P
 454465-69-1P 454465-70-4P 454465-71-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

of (drug candidate; prepn. of aminodicarboxylic acids for the treatment of cardiovascular diseases via the activation of sol. guanylate cyclase (sGC))

RN 454465-59-9 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)[2-[2-[[3-fluoro-4'-methoxy[1,1'-biphenyl]-4-yl)methoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 454465-60-2 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)[2-[2-[[4'-(1,1-dimethylethyl)-3-fluoro[1,1'-biphenyl]-4-yl)methoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Kamal Saeed

L3 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN
 ACCESSION NUMBER: 2002:671700 CAPLUS

DOCUMENT NUMBER: 137:201148
 TITLE: Preparation of aminodicarboxylic acids for the treatment of cardiovascular diseases
 INVENTOR(S): Haerter, Michael; Hahn, Michael G.; Hirth-Dietrich, Claudia; Knorr, Andreas; Stahl, Elke; Stasch, Johannes-Peter; Wunder, Frank
 PATENT ASSIGNEE(S): Bayer AG, Germany
 SOURCE: Ger. Offen., 20 pp.
 CODEN: GWFOEX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10109861	A1	20020905	DE 2001-10109861	20010301
WO 2002070461	A1	20020912	WO 2002-EPI895	20020222


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TH, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, ML, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 EP 1368301 A1 20031210 EP 2002-716805 20020222
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 US 2004082658 A1 20040429 US 2003-469178 20030826
 PRIORITY APPLN. INFO.: DE 2001-10109861 A 20010301
 WO 2002-EPI895 W 20020222
 OTHER SOURCE(S): HARPAT 137:201148
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [R1 = halo; R2 = H, halo; R3 = (un)substituted Ph, cycloalkyl, cycloalkenyl] and their pharmaceutically acceptable salts prep. For example, condensation of phenol II, prep. from 2-methoxyphenylethylamine in 3-steps, with 4-(chloromethyl)-3-fluoro-4'-methoxy-1,1'-biphenyl, followed by ester hydrolysis afforded aminodicarboxylic acid III. In vitro artery ring vasorelaxation activity of 4-examples of I are reported, with IC50 values ranging from 2-0.15 nM. Compds. I stimulated the activation of sol. guanylate cyclase (sGC) independent of the heme group.

IT 454465-61-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP


L3 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)



RN 454465-62-4 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)[2-[2-[[3-chloro-4'-methoxy[1,1'-biphenyl]-4-yl)methoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 454465-63-5 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)[2-[2-[[3-chloro-4'-fluoro[1,1'-biphenyl]-4-yl)methoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 454465-64-6 CAPLUS

10088060

L3 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 CN Benzoic acid, 4-[[[(4-carboxybutyl)[2-[2-[[3-chloro-4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 454465-65-7 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl)[2-[2-[[4'-chloro-3-fluoro[1,1'-biphenyl]-4-yl]methoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 454465-66-8 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl)[2-[2-[[4-(1-cyclohexen-1-yl)-2-fluorophenyl]methoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 454465-69-1 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl)[2-[2-[[4-cyclohexyl-2-fluorophenyl]methoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 454465-70-4 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl)[2-[2-[[2-chloro-4-cyclohexylphenyl]methoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 454465-71-5 CAPLUS

Kamal Saeed

L3 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 454465-67-9 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl)[2-[2-[[2-chloro-4-(1-cyclohexen-1-yl)phenyl]methoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 454465-68-0 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl)[2-[2-[[3-chloro-4'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl]methoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)


CN Benzoic acid, 4-[[[(4-carboxybutyl)[2-[2-[[3-fluoro-4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]phenyl]ethyl]amino]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 454465-76-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; prepn. of aminodicarboxylic acids for the treatment of cardiovascular diseases via the activation of sol. guanylate cyclase (sGC))

RN 454465-76-0 CAPLUS
 CN Benzoic acid, 4-[[[(5-ethoxy-5-oxopentyl)[2-[2-[[3-fluoro-4'-methoxy[1,1'-biphenyl]-4-yl]methoxy]phenyl]ethyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



10088060


L3 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN
 ACCESSION NUMBER: 2002:671698 CAPLUS
 DOCUMENT NUMBER: 137:201147
 TITLE: Preparation of aminodicarboxylic acids for the treatment of cardiovascular diseases
 INVENTOR(S): Haerter, Michael; Hahn, Michael G.; Hirth-Dietrich, Claudia; Knorr, Andreas; Stahl, Elke; Stasch, Johannes-Peter; Wunder, Frank
 PATENT ASSIGNEE(S): Bayer AG, Germany
 SOURCE: Ger. Offen., 30 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10109859	A1	20020905	DE 2001-10109859	20010301
WO 2002070459	A1	20020912	WO 2002-EP1682	20020218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1368302	A1	20031210	EP 2002-718141	20020218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004110840	A1	20040610	US 2003-469557	20030829
PRIORITY APPL. INFO.: DE 2001-10109859 A 20010301 WO 2002-EP1682 W 20020218				
OTHER SOURCE(S): MARPAT 137:201147				
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R1 = H, halo or OCF3 meta or para to R2; R2, R3 = H, halo; R4 = alkyl, cycloalkyl, CF3, etc.; V = O, CH2O, CF2O, etc., ortho or meta to W; W = CH2, CH2CH2] and their pharmaceutically acceptable salts were prepd. For example, Pd(Ph)4 mediated coupling of aryl bromide II, prepd. from 2-methoxyphenylethylamine in 4-steps, with 4-trifluoromethylphenyl boronic acid, followed by ester hydrolysis afforded aminodicarboxylate III. In vitro artery ring vasorelaxation activity of 5-examples of I are reported, with IC50 values ranging from 35-0.041 nM. Compds. I stimulated the activation of sol. guanylate cyclase (sGC) independent of the heme

L3 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 mino[methyl]- (9CI) (CA INDEX NAME)




RN 454466-88-7 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl)[3-(4-cyclohexylphenoxy)phenyl]methyl]amino]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 454466-89-8 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl)[3-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]oxy]phenyl]methyl]amino]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 454466-90-1 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl)[3-[[4'-fluoro[1,1'-biphenyl]-4-yl]oxy]phenyl]methyl]amino]methyl]-, hydrochloride (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
 group.
 IT 454466-87-6P 454466-92-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; prepn. of aminodicarboxylic acids for the treatment of cardiovascular diseases via the activation of sol. guanylate cyclase (sGC))
 RN 454466-87-6 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl)[3-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]oxy]phenyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 454466-92-3 CAPLUS
 CN Benzoic acid, 4-[[[(2-[2-[[1,1'-biphenyl]-4-yl]difluoromethoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




IT 454466-86-5P 454466-88-7P 454466-89-8P
 454466-90-1P 454466-91-2P 454466-93-4P
 454466-94-5P 454466-95-6P 454466-96-7P
 454466-97-8P 454466-98-9P 454466-99-0P
 454467-00-1P 454467-01-2P 454467-02-3P
 454467-03-4P 454467-04-5P 454467-05-1P
 454467-06-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prepn. of aminodicarboxylic acids for the treatment of cardiovascular diseases via the activation of sol. guanylate cyclase (sGC))
 RN 454466-86-5 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl)[3-(4-cyclohexylphenoxy)phenyl]methyl]amino]methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)




● HCl

RN 454466-91-2 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl)[2-[2-[[4'-fluoro[1,1'-biphenyl]-4-yl]methoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 454466-93-4 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl)[2-[2-[[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl]difluoromethoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 454466-94-5 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl)[2-[2-[[4'-chloro[1,1'-biphenyl]-4-yl]difluoromethoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

10088060


L3 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 454466-95-6 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)[2-[2-(difluoro(4'-methoxy[1,1'-biphenyl]-4-yl)methoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 454466-96-7 CAPLUS
 CN Benzoic acid, 4-[[[2-[2-[[1,1'-biphenyl]-4-yl]difluoromethoxy]phenyl]ethyl] (4-carboxybutyl)amino]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 454466-97-8 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)[2-[2-[(4-cyclohexylphenoxy)methyl]-5-


L3 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 454466-98-9 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)[2-[2-[[[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl]oxy]methyl]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 454466-99-0 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)[2-[5-fluoro-2-[[[4'-fluoro[1,1'-biphenyl]-4-yl]oxy]methyl]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 454467-00-6 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)[2-[5-fluoro-2-[[[4'-methoxy[1,1'-biphenyl]-4-yl]oxy]methyl]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 454467-01-7 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)[2-[2-[[[4'-chloro[1,1'-biphenyl]-4-yl]oxy]methyl]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 454467-02-8 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)[2-[5-fluoro-2-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]oxy]methyl]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 454467-03-9 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)[2-[2-[[[4'-cyano[1,1'-biphenyl]-4-yl]oxy]methyl]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 454467-04-0 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)[2-[2-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]oxy]methyl]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)






RN 454467-05-1 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)[2-[2-[[[4'-methoxy[1,1'-biphenyl]-4-yl]oxy]methyl]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 454467-06-2 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)[2-[2-[[[4'-chloro[1,1'-biphenyl]-4-yl]oxy]methyl]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



L3 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:671697 CAPLUS
DOCUMENT NUMBER: 137:201146
TITLE: Preparation of aminodicarboxylic acids for the
treatment of cardiovascular diseases
INVENTOR(S): Haerter, Michael; Hahn, Michael G.; Hirth-Dietrich,
Claudia; Knorr, Andreas; Stahl, Elke; Steach,
Johannes-Peter; Wunder, Frank
PATENT ASSIGNEE(S): Bayer AG, Germany
SOURCE: Ger. Offen., 20 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10109858	A1	20020905	DE 2001-10109858	20010301
WO 2002070460	A1	20020912	WO 2002-EPI683	20020218
M:	AE, AG, AL, AM, AT, AU, AZ,	BA, BB, BG, BR, BY, BZ,	CA, CH, CN,	
C, CR, CU, CZ, DE, DK, DM,	DZ, EE, EG, ES, FI, GB, GD,	GE, GH,		
GM, HR, HU, ID, IL, IN, IS,	JP, KE, KG, KP, KR, KZ, LK,	LR,		
LS, LT, LU, LV, MA, MD, MG,	MK, MN, MW, MX, MY, NZ,			
PL, PT, RO, RU, SD, SE, SG,	SI, SK, SL, TJ, TN, TR,	TT, TZ,		
UA, UG, US, UZ, VN, YU,	ZA, ZM, ZW, ZA, ZY,	BH, KG, KZ,		
TJ, TM, TW, UA, UG, US, UZ, VN, YU,	ZA, ZM, ZW, ZA, ZY,	BH, KG, KZ,		
RW: GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, UM, ZW, AT, BE, CH,				
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR,				
BF, BF, CF, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1368303	A1	20031210	EP 2002-179859	20020218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, GT, IT, LI, LU, NL, SE, NC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004092593	L1	20040513	US 2003-1469180	20030826
PRIORITY APPLN. INFO.:			DE 2001-10109858 A	20010301
			WO 2002-EPI683	W 20020218
OTHER SOURCE(S):		MARPAT 137:201146		
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. [R1 = halo meta or para to ethylamine; R2 R3 = H, halo; R4 = cycloalkyl, (un)substituted Ph] and their pharmacologically acceptable salts were prepd. For example, N-alkylation of benzylic amine II, prepd. from 4-fluoro-2-hydroxybenzaldehyde in 4-steps, with 5-bromopentanoic acid Me ester, followed by ester hydrolysis afforded aminodicarboxylic acid III. In vitro artery ring vasorelaxation activity of 5-examples of I are reported, with ED₅₀ values ranging from 0.3-1.0 μM. I also stimulated the activation of gG₁₂ guanylyl cyclase (gGC) in an NO-independent

IT 434664-21-2P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

L3 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN (Continued)
CN Benzoic acid, 4-[[[2-[2-(difluoro[4'-(trifluoromethyl)]1,1'-biphenyl)-4-yl]methoxy]phenyl]ethyl][5-methoxy-5-oxopentyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 454464-21-2 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)(2-[2-[(4-cyclohexylphenyl)methoxy]-4-fluorophenyl]ethyl)amino]methyl]- (9CI) (CA INDEX NAME)



RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Uses)
of (drug candidate; prepn. of aminodicarboxylic acids for the treatment of cardiovascular diseases via the activation of sol. guanylate cyclase)


RN 454464-22-3 CAPLUS
 CN Benzoic acid, 4-[[[(4-carboxybutyl)[2-[2-[(4-cyclohexylphenyl)methoxy]-5-fluorophenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 454464-23-4 CAPLUS
CN Benzoic acid, 4-[[[4-carboxybutyl][2-[5-chloro-2-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methoxy]phenyl]ethyl]amino]methyl]-
(9CI) (CA INDEX NAME)

10088060


L3 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 454464-24-5 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)2-[5-chloro-2-[(4'-methoxy(1,1'-biphenyl)-4-yl)methoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 454464-25-6 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)2-[5-chloro-2-[(4'-methoxy(1,1'-biphenyl)-4-yl)methoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 454464-26-7 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)2-[5-chloro-2-[(4'-methoxy(1,1'-biphenyl)-4-yl)methoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)


L3 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 454464-27-8 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)2-[5-chloro-2-[(4'-fluoro(1,1'-biphenyl)-4-yl)methoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 454464-28-9 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)2-[5-chloro-2-[(4'-cyano(1,1'-biphenyl)-4-yl)methoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 454464-29-0 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)2-[5-chloro-2-[(3-chloro-4'-methoxy(1,1'-biphenyl)-4-yl)methoxy]phenyl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)




RN 454464-30-3 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)2-[2-[(4-cyclohexylphenyl)methoxy]-4-fluorophenyl]ethyl]amino]methyl]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 454464-31-4 CAPLUS
 CN Benzoic acid, 4-[[[4-(4-carboxybutyl)2-[2-[(4-cyclohexylphenyl)methoxy]-4-fluorophenyl]ethyl]amino]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 454464-37-0P

Kamal Saeed

L3 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; prepn. of aminodicarboxylic acids for the treatment of cardiovascular diseases via the activation of sol. guanylate cyclase (sGC))

RN 454464-37-0 CAPLUS
 CN Benzoic acid, 4-[[[2-[2-[(4-cyclohexylphenyl)methoxy]-4-fluorophenyl]ethyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



10088060

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

81.35

237.40

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-11.76

-11.76

STN INTERNATIONAL LOGOFF AT 10:16:23 ON 12 JUL 2004